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INTRODUCTION 
 
1.1 General introduction 
Inflammation and metabolism are intrinsically linked, and chronic, systemic inflammation is 
an essential feature of metabolic syndrome (2). Inflammatory responses crosstalk with 
intracellular stress signaling pathways through a variety of professional cells of immune and 
metabolic features, such as adipocytes, macrophages, hepatocytes, and pancreatic β cells.  
Increasing evidence suggests that the integrated inflammatory stress responses modulate 
energy metabolism in these professional cells, contributing to the initiation and progression of 
metabolic diseases, such as obesity, type-2 diabetes, and atherosclerosis (3). Integrated 
inflammatory stress responses and their pathophysiological impact in metabolism have been a 
hot research topic in the past decade. However, an in-depth mechanistic understanding of the 
crosstalk between the intracellular stress signaling pathways and inflammatory responses, and 
their participation in disease progression remains to be further elucidated. Understanding the 
molecular networks underlying inflammation-modulated metabolism may lead to 
identifications of lucrative targets for pharmaceutical interventions or therapeutic benefits 
towards controlling diseases. This thesis research was focused on elucidating one such cross-
talk between innate immunity and liver metabolism, mediated through a stress-inducible, liver-
specific transcription factor, CREBH, under the endotoxin/ lipopolysaccharide (LPS) 
treatment. 
LPS,  a component of the gram-negative cell wall, is one of the potent factor capable of 
inducing a significant immune response in acute and chronic infection. It is a unique glycolipid 
located at the outer membrane of the bacteria. LPS is not found free in circulation, 80–97% of 
it is attached to the lipoproteins (4).  The task of neutralization and clearance of LPS is mediated 
by HDLs in circulation (5). Circulating bacterial endotoxins are capable of causing acute as 
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well as systemic infections. The primary route of endotoxin contribution is through 
translocation of endotoxins from gut microbiota. The significant role of endotoxin in metabolic 
and cardiovascular disease has been proved through studies on germ free animals (6, 7). 
Endotoxins are capable of activating both adaptive and innate immune systems leading to the 
release of antibodies, cytokines, and other inflammatory mediators, which causes hepatic 
insulin resistance (8, 9). Treating rats with an antibiotic specifically targeted against gram-
negative bacteria reduces the production of TNFα by macrophages, thereby reducing steatosis 
(10). 
In humans, high-fat diet increases body weight and induces insulin resistance.  The 
primary cause of the high-fat diet-induced metabolic syndrome associated with endotoxin 
originated from gut microbiota (11). These types of diets cause compromised intestinal 
permeability by altering the tight junctions in cells (12). Altered permeability is one of the main 
underlying reasons behind the phenomenon termed “metabolic endotoxemia”. The severity of 
inflammation may depend on a complex interplay between specific proteins, receptors, and 
lipoproteins that mediate the endotoxin bioactivity and metabolic fate (13). 
The richness of fat in western food makes the western countries more susceptible to 
different metabolic outbreaks. Etiology of obesity is closely associated with the intricate 
interaction between genetic and environmental factors (14). Metabolic syndromes like obesity 
and diabetes are the classical example of the influence of diet on human health.  The significant 
effect of high-fat diet is through impairment of insulin signaling and the signaling associated 
with body weight maintenance (15). In addition, it has been recently determined that obesity 
and insulin resistance are associated with low-grade chronic systemic inflammation (16). In the 
diet-induced models for obesity, obese animals displayed increased levels of proinflammatory 
cytokines, such as tumor necrosis factor TNF-α, interleukin IL-1, and IL-6 were detected (17). 
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Production of such proinflammatory cytokines has harmful effect on action of insulin; for 
example, TNF-α mediated  insulin resistance is through increasing serine phosphorylation on 
insulin receptor substrate-1, leading to its unresponsiveness to insulin signaling (18-20). The 
consequence of such impaired insulin signaling will cause hyperinsulinemia and increase in 
hepatic and adipose tissue lipid storage. However, all the research focus has been dedicated to 
the effect of an inflammatory reaction in body metabolism; the actual triggering factors 
connecting inflammatory stress to metabolic syndrome is still elusive (21). Recently, it has 
been demonstrated that fatty acids from the diet can induce activation of Toll-Like Receptor 4 
(TLR4) signaling pathways in adipocytes and macrophages (22). Besides regular ligands, the 
metabolites generated during lipolysis in adipose tissues also serve as potential TLR4 ligands 
(23). 
A new paradigm has recently been proposed that points out to the importance of human 
microflora in influencing the energy homeostasis in metabolic disease. The primary hypothesis 
was backed up by the evidence that obese individuals were associated with gut microbiota, and 
aberrant condition of gut microbiota promotes  metabolic disease occurrence (24). A recent 
study has reported that the treatment of diabetes susceptible rats with antibiotics protect them 
from insulitis (25). The possible explanations behind this are that treatment with antibiotics 
changes the composition of gut microbiota, subsequently reducing the load of potential TLR 
ligands. Since, there is a decrease in the ligand, it leads to a reduction in proinflammatory 
cytokine production. From this viewpoint, we have been investigating a mechanism originating 
from the microbial component that trigger hepatic metabolic changes. We hypothesized that 
the bacterial LPS from the gram-negative intestinal microbiota would fulfill all the 
prerequisites to be an eligible ligand for our study. It has been established that endogenous LPS 
is: 1) continuously produced in the gut by the death of gram-negative bacteria and 
physiologically translocated into intestinal capillaries through a TLR4-dependent mechanism; 
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2) able to reach from the intestine toward target tissues, i.e., liver mediated by lipoproteins, 
notably chylomicrons freshly synthesized by epithelial intestinal cells in response to a high-fat 
diet; and 3) eliciting the production of proinflammatory cytokines when it binds to the complex 
of mCD14 and the TLR4 at the surface of innate immune cells. In my thesis research, I aimed 
to demonstrate a novel molecular link through which LPS could modulate lipid metabolism 
under metabolic and/or inflammatory condition. 
Among the stressors, microbial components, such as peptidoglycan and LPS can affect 
the growth performance and also modulate the metabolism. Additionally, recent biomedical 
evidence suggests that the low-grade inflammation caused by intestine- derived LPS is linked 
to metabolic diseases, such as Type II diabetes, atherosclerosis, and cardiovascular diseases 
(26).  Importantly, the intact mucosa from the gastrointestinal tract acts as a mechanical barrier 
for bacteria in the intestinal lumen; a primary source of LPS (27). LPS in mammals is 
recognized by various cells expressing the pattern recognition receptor and other proteins 
including LPS binding protein (LBP), a cluster of differentiation 14 (CD14), and MD-2. These 
proteins and receptors are shown to be present in most of the cells from the liver and have been 
ascribed  role in the permeability of luminal LPS into circulation (28). Once in the systemic 
circulation, detoxification of LPS can be carried by immune cells, such as macrophages, 
Kupffer cells, and splenic cells, or even by binding to plasma proteins. However, if there is 
failure in  detecting and deactivating the circulating LPS, increased intestinal permeability may 
increase circulating LPS concentrations that eventually lead to systemic inflammation, 
endotoxemia, multi-organ failure, and even death (29). 
In human health, presence of LPS in the circulation have been shown to contribute to 
the development of chronic inflammatory processes that promote the development of 
dysregulated metabolism which results in many metabolic diseases such as type II diabetes and 
non-alcoholic fatty liver disease (NAFLD) through the stimulation of TLR4. Interestingly, the 
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permeability of LPS from the intestine has been shown to be regulated by various factors such 
as dietary factors, and different stressors, such as heat, infection, and malnutrition. The major 
dietary factor that appears to modulate the permeability of luminal LPS is dietary fats. As the 
percentage of dietary fats increases, so does the concentration of circulating LPS (30). Further 
studies are warranted to investigate the relationship between LPS and metabolic changes. 
 
1.2 Structure of bacterial LPS 
The structure of LPS consist of three main part; a hydrophobic domain, lipid A, through 
which it is anchored into the outer leaflet of the outer membrane of the bacterial cell wall, a 
core oligosaccharide, and a distal oligosaccharide (31). The hydrophobic lipid A domain is the 
immunogenic part of the LPS molecule, and it is often used as ‘endotoxin’ because of its ability 
to stimulate the innate immune cells. In a wild-type Escherichia coli, lipid A contains the 
following structural properties: 1) the backbone of the lipid A contains di-glucosamine, which 
is phosphorylated at positions 1 and 4', 2) two 3-hydroxymyristate molecules are directly 
attached to each glucosamine, and 3) at positions 2' and 3', the hydroxyl groups of  the fatty 
acids are substituted by laurate and  myristate, and they form an acyloxyacyl bond  with the 
primary fatty acid chains (32).  
 
1.3 Microbiota and human metabolism 
Gut microbiota primarily inherited from the intestinal bacteria that are acquired from 
the mother first and subsequently modified by surrounding environment immediately after 
birth. Establishment of microbiota  takes about few months and tend to remain stable for a 
lifetime with minimal variation. The microflora in a different segment of gastrointestinal tracts, 
however, displays variability in both density and species. Tiny numbers of microorganisms 
colonize in the stomach and the duodenum, whereas the lower gastrointestinal tract harbors 
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progressively increased number of microbes. Despite up to 1,000 species of microorganisms 
colonize the whole intestinal tract, the gut immunity fitness is maintained over the time of life.  
Pathological stimuli, such as immunosuppressive drugs, radiations, and chemicals, can lead to 
alteration in the gut microbiota. 
Microorganism in the digestive tract also offers much beneficiary functions for 
harboring hosts. For instance, intestine microorganisms contribute to the synthesis of short 
chain fatty acids, the number of which serves substrate in energy metabolism process. 
Propionate that is a substrate for both gluconeogenesis and de novo lipogenesis in hepatocytes 
is produced by microbiota. Obesity-associated microbiota modulation has been reported in both 
animal and human studies (33). In another animal study, two dominant bacterial divisions in 
the gut microbial community were reported to have distinct abundance in genetically obese 
ob/ob mice in comparison to their lean littermates: relatively fewer Firmicutes while more 
Bacteroidetes (34). Furthermore, microbiota from ob/ob mice showed an efficient ability to 
harvest energy from the indigestible diet in the intestine than microbiota from their lean 
littermates. In humans, it is reported that the ratio of Firmicutes to Bacteroidetes was notably 
higher in obese subjects than lean people. Furthermore, increased abundance of Bacteroidetes 
correlates with a degree of weight-loss following fat restricted or carbohydrate-restricted 
dietary interventions. Taken together, these findings suggest that the alteration of microbiota 
plays an important role in terms of  outcomes associated with obesity and its related metabolic 
disorders in both animals and humans. 
 
1.4 Endotoxemia in metabolic disorders 
 
One of the significant contributions of altered gut microbiota in metabolic disorders is 
the elevation of circulating LPS.  As mentioned before, high-fat diet (HFD) results in an 
increased amount of the LPS-containing microbiota in the intestine and a subsequently causes 
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elevation of circulating LPS levels. Confirming these results are the observation from human 
studies. Blood endotoxin (LPS) levels in healthy human subjects were significantly high after 
a high-fat meal (35). Several mechanisms have been proposed to explain why high-fat diet 
causes endotoxemia. Genetically obese ob/ob and db/db mice had increased portal endotoxin 
levels. This leads to enhanced intestinal permeability, and eventually increased circulating 
cytokine levels relative to lean control mice (36). New research provide an evidence that lipid 
facilitate absorption of LPS in intestine In vitro incubation of human intestinal epithelial Caco-
2 cells with oleic acid, a long-chain fatty acid that can induce chylomicron formation, resulted 
in more release of cell-derived LPS, whereas this effect of oleic acid is abolished after the 
blockade of chylomicron formation by Pluronic L-81 (36). Consistently, in vivo study also 
showed that administration of LPS with oil induces significant effect than the mixture with 
water (9). The circulating LPS is an important player in the pathogenesis of obesity-related 
metabolic disorders. In mice on normal chow, continuous LPS infusion caused a cluster of 
metabolic disorders, including hyperglycemia, hyperinsulinemia, as well as increased body 
weight (37). Most strikingly, these LPS-induced metabolic alterations in normal chow-fed mice 
were comparable to those in mice upon high-fat diet feeding.  Not only endotoxemia affects 
the local adipose tissue and muscles they also exert profound influences on energy metabolism 
in the liver. Chronically subcutaneous infusion of LPS in vivo leads to hepatic insulin resistance 
and excessive hepatic triglyceride accumulation. Intriguingly, LPS-stimulated hepatic insulin 
resistance and steatosis are almost entirely suppressed in CD14-deficient mice (38). Overall, 
these data demonstrated the potential link between low-grade endotoxemia and metabolic 
disorders. 
Infection and inflammation can cause significant changes in lipid and lipoprotein 
metabolism that result in increased circulating free fatty acids (FAs), hypertriglyceridemia, and 
altered plasma HDL levels. These changes are mediated by cytokines, such as interleukins 
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(IL6, IL1β), tumor necrosis factors (TNF-α and TNF-β), and interferons (IFN-α, IFN-β, and 
IFN-γ) (39). These mediators are also increased in several low-degree inflammation disorders 
like atherosclerosis, obesity, metabolic syndrome and diabetes that show abnormalities in lipid 
metabolism similar to those found during infection and inflammation (39, 40). 
There are several lines of evidence supporting the idea of an intricate network of 
relationships between inflammatory responses and lipid biology, including that of lipid droplets 
(LDs). It has been shown that administration of TNF-α, induce modifications in the surface of 
LDs and also promote an increase in lipolysis in adipocytes (41). On the other hand, clinical 
samples from sepsis patient tend to show accumulation of LDs and association of inflammatory 
proteins with LDs (42).  Injection of endotoxins in rats displayed increased levels of serum 
VLDL-ApoB (10-fold), -triglyceride (2-fold), and -cholesterol (2-fold). Similarly, the 
hepatocytes isolated from such endotoxic mice secreted more VLDL-ApoB than their 
comparable controls. Currently, little is known about the mechanism of crosstalk between the 
body’s immune system and metabolism. My thesis work uncovers one of the aspects and a 
mechanism underlying previously noted metabolic changes associated with endotoxemia. 
Infection and inflammation are accompanied by similar cytokine-induced alterations in lipid 
and lipoprotein metabolism. 
 
1.5 Innate immune signaling 
The innate immune system provides protection against a large variety of pathogens, 
possible through its array of receptors called pattern recognition receptors (PRRs). These 
receptors recognize specific and conserved molecular patterns or domain of pathogens. The 
PRRs include the members of the TLRs family and the nucleotide-binding oligomerization 
domain proteins (NOD-like receptors, NLRs). 
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TLRs belong to the type I transmembrane proteins that have distinct domains, an 
extracellular leucine-rich domain (LRR) and an intracellular or cytoplasmic domain 
homologous to the interleukin-1 receptor (IL-1R) and therefore called Toll/IL-1 receptor (TIR) 
domain. LPS is recognized and signaled by the PRR, TLR4 (43). However, the presence of 
LPS is not sensed by TLR4 alone. LPS is generally present in clumps bound to other LPS 
molecules on which LBP leeches out a monomer that is then presented to a co-receptor called 
as a CD14 receptor. The CD14 receptor is present in two forms, membrane-bound (mCD14) 
or soluble (sCD14) (44).The CD14 protein lacks an intracellular domain so it associates with 
TLR4, which has a Toll-interleukin 1 receptor (TIR) intracellular domain through which it can 
transmit the intracellular signal. TLR4 then dimerizes with MD-2, which transmits the signal 
through the TIR intracellular domain through two different pathways. One is a myeloid 
differentiation factor 88 (Myd88)-dependent and the other one is a Myd88-independent 
pathway. The first pathway leads to translocation of nuclear factor kappa beta (NFκB) to the 
nucleus and the initiation of transcription of inflammatory mediators. Alternately, the 
independent pathway leads to the activation of interferon regulatory factor 3 (IRF3) as well as 
NFκB (45). Both pathways lead to the secretion and stimulation of pro-inflammatory cytokines 
and other immune mediators. TLR4 signaling is quenched by endocytosis of TLR4, along with 
LPS, to an endosome where it is then degraded (46). Current research indicates that apart from 
the signaling protein, the role of lipid rafts are essential for TLR4 signaling  and permeability 
through the membrane to occur (47, 48). Lipid rafts have also been implicated in endocytosis 
of pathogens (49). Interestingly, TLR4 has been shown to localize to these membrane lipid raft 
domains upon LPS stimulation, and disruption of LPS signaling occurs if the lipid raft is 
dissociated (50). Further saturated, and unsaturated fats have been shown to modulate the TLR4 
localization reciprocally into lipid raft and its signaling. Saturated fatty acids stimulate the 
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TLR4 to localize into rafts and start the inflammatory signaling cascade whereas n-3 PUFA’s 
prevent the stimulation and localization into lipid raft (51). 
 
1.6 TLR4 and ligands 
 
TLRs sense signals derived from invading pathogens through the recognition of 
pathogen-associated molecular patterns (PAMPs). LPS was the first PAMP discovered, which 
was initially described as “endotoxin” by Richard Pfeiffer in the year 1892. Serving as a 
component of the outer membrane of gram-negative bacteria, LPS has been well-characterized 
as the most common ligand of TLR4. As mentioned previously, LPS is structurally composed 
of three portions, including a predominantly lipophilic region (lipid A), a hydrophilic core 
oligosaccharide, and a polysaccharide chain (O-polysaccharide). The lipid A part is the 
significant portion responsible for TLR4- agonist effect of LPS. The O-polysaccharide region 
shows variations in different forms of LPS. LPS in some types of bacteria does not contain O-
polysaccharide portion, known as “rough LPS”. Conversely, LPS containing O-polysaccharide 
is named as “smooth LPS”. The rough and smooth form of LPS activates TLR4 in different 
manners. Rough LPS may activate TLR4 independently of LPS-binding protein (LBP) and 
CD14 whereas LBP and CD14 are required for smooth LPS-mediated TLR4 activation.  On 
the other hand, TLR4 activation caused by smooth LPS in the presence of LBP and CD14 may 
be more efficient than that induced by rough LPS. (52) 
Besides LPS, a  cluster of molecules released after  cellular damage or wound healing 
responses have been  demonstrated to have binding ability to induce TLR4 signals, such as 
high mobility group protein b-1 (HMGB1) and hyaluronan. A specific term, damage-associated 
molecular patterns (DAMPs), has been coined to describe this class of molecules with the 
TLR4-agonist activity (53). HMGB1 is a 30-kDa heparin-binding protein which exerts both 
transcription factor-like and cytokine-like functions in cells undergoing apoptosis and necrosis 
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(54). Furthermore, HMGB1 can catalytically disaggregate and transfer LPS to both soluble 
CD14 protein and human peripheral blood monocyte (PBMCs). In addition, treatment with a 
mixture of HMGB1 and LPS resulted in significant production of TNF-α production in human 
PBMCs than LPS or HMGB1 treatment alone, suggesting that HMGB1 facilitates LPS to 
induce TLR4-mediated proinflammatory response (55). FAs have been also demonstrated to 
induce TLR4-mediated inflammatory signals. In macrophages, treatment with saturated FA led 
to NF-κB activation, COX-2 expression, as well as proinflammatory cytokine IL-1α 
production. A dominant-negative TLR4 blocked this effect, suggesting that an indispensable 
role of TLR4 in unsaturated FA-induced inflammatory response in macrophages. Likewise, 
another study reported that FAs activated TLR4 signaling in macrophages, adipose cells, and 
tissues (56). 
 
1.7 Innate immunity in the liver 
 
 Out of the conventional arterial system blood supply the majority (about 80%) of blood 
entering the liver through a portal vein that is rich in gut content. This leads to exposure of the 
liver to an array of immunogenic stimuli. The enriched bacterial products and environmental 
toxins in the portal blood stream are transported to the liver. The immune system responds to 
both endogenous and foreign harmless antigens to avoid abnormal and excessive immune 
response causing tissue damage (57). Hence, innate immunological components are 
predominant in liver immunity. On the one hand, innate immune cells, including macrophages 
(Kupffer cells), NKT cells, and NK cells are selectively enriched in the liver. In a healthy liver, 
Kupffer cells constitute about 20% of mesenchymal cells (58). The number of macrophages in 
the liver (liver resident and circulating macrophages) is further elevated in response to several 
stimuli. NKT cells, accounting for up to 30% of the hepatic lymphocyte fraction, are abundant 
in the liver than other organs (59). On the other hand, liver cells produce several factors 
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participating in systemic innate immunity, such as inflammatory cytokines, chemokines, and 
complement components. Therefore, innate immunity plays a crucial role in maintaining the 
homeostasis and the defense of pathogens in the liver. 
Recognition and initiation of inflammation is a key in the development of NAFLD. In 
NAFLD patients as well as animal models, NF-κB activation is observed in liver cells, 
including hepatocytes, hepatic stellate cells, and Kupffer cells. NF-kB activation elevates in 
NAFLD.  NF-kB activation plays an important role in proinflammatory cytokine and 
chemokine productions. It also plays a major role in insulin resistance. It is unclear whether 
NF-κB activation in hepatocytes leads to steatosis. Hepatocyte-specific IKKβ overexpression 
induces steatosis. In contrast, NF-κB essential modulator (NEMO) deficiency in hepatocytes 
results in spontaneous steatohepatitis (60). NEMO deficiency completely blocks NF-κB 
activation, indicating that NF-κB activation in hepatocytes is not a primary cause of steatosis.  
One of the important function of NF-kB is activation of TNFα genes, which in turn exerts a 
significant effect on NAFLD outcome (61). 
 
1.8 Inflammation, stress response, and Non-Alcoholic Fatty Liver Disease 
(NAFLD) 
NAFLD represents a spectrum of diseases ranging from simple fatty liver (steatosis) to 
nonalcoholic steatohepatitis (NASH), to irreversible cirrhosis. NAFLD is the most common 
chronic liver disease in Western countries and is considered the hepatic manifestation of 
metabolic disorders including visceral obesity, diabetes mellitus, dyslipidemia, and 
hypertension (60). The hallmark of NAFLD is characterized by excessive accumulation of 
hepatic lipid, mainly triglycerides, in the absence of significant ethanol consumption, viral 
infection, or other specific etiologies. The development of a state of non-alcoholic hepatic 
steatosis may be caused by an increased uptake of lipids by the liver, an increased hepatic 
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synthesis of fatty acids, decreased oxidation of fatty acids and/or decreased synthesis or 
secretion of very low density lipoproteins (VLDLs). The progression from hepatic lipid 
accumulation and steatosis to NASH is explained by a “two-hit” working model (62). 
According to this model, steatosis represents the “first hit,” which increases the vulnerability 
of the liver to various “second hits” induced by endotoxin, oxidative stress, saturated fatty 
acids, or other liver injuries. The “second hits” will subsequently lead to the inflammation, 
fibrosis and cellular death characteristic of steatohepatitis. Consistent with this model, 
administration of variously proposed second hits (e.g., endotoxin and pro-oxidants) results in 
significantly greater liver damage and lethality in obese mice with fatty liver compared to lean 
mice with healthy livers. Furthermore, in humans, the severity of steatosis is one of the 
strongest predictors of the development of NASH. Several factors have been suggested to 
constitute the second hit(s), most notably oxidative stress, pro-inflammatory cytokines, and 
gut-derived bacterial endotoxin. The effects of the “two hits” are not mutually exclusive, but 
act in a coordinated and cooperative manner to hasten the development and progression of 
NASH. For example, excess fatty acids are associated with increased proinflammatory 
cytokines and oxidative stress, as well as an exaggerated inflammatory response to endotoxin 
administration. In environments conducive to the generation of various second hits, for 
example, obesity, a vicious cycle of insults may cause liver injury and culminate in NASH and 
end-stage liver disease. Despite this knowledge, numerous critical questions remain 
unanswered. For example, what are the molecular determinants that mediate the effects of “first 
hit” and/or “second hit” in the development of NAFLD? What metabolic signaling initiates the 
development of NAFLD? Investigations of these questions will have important implications 
for understanding the pathways that control hepatic steatosis and steatohepatitis and will be 
informative to prevention and treatment of human NAFLD and its associated metabolic 
syndrome. 
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1.9 Hepatic lipid metabolism 
 
In the liver, the lipid content is regulated by dietary FA or carbohydrates uptake, hepatic 
FA biosynthesis, esterification, oxidation, and export. Dietary carbohydrates are partly 
consumed for normal bodily functions and metabolized to glycogen or FAs in the liver if in 
excess (63). Fatty acids are esterified to triglycerides (TG) and then either be stored in 
cytoplasmic lipid droplets or incorporated into VLDL particles and secreted into the blood. 
Additionally, TG can also be hydrolyzed, and the fatty acids are destined towards the oxidation 
pathway. Conversion of carbohydrates to TG involves two steps: glycolysis which generates 
acetyl-CoA from glucose, and lipogenesis that converts acetyl-CoA to fatty acids. Enzymes 
involved in glycolytic and lipogenic pathways are dynamically regulated at both transcriptional 
and post-translational levels by various factors such as substrate concentrations and hormones. 
Pancreatic hormones, insulin, and glucagon play critical roles in the transcriptional regulation 
of these enzymes. For example, insulin can reduce hepatic glucose production through 
decreasing glycogen breakdown (glycogenolysis) and increasing the rate of glucose uptake, 
primarily into skeletal muscle and adipose tissue. Insulin can also stimulate FA biosynthesis 
by activating the sterol regulatory element binding protein-1c (SREBP-1c) transcription factor 
that activates the expression of lipogenic genes involved in FA synthesis and TG synthesis (64, 
65). During fasting, glucagon activates the protein kinase A, which phosphorylates 
carbohydrate response element-binding protein (ChREBP), preventing its translocation to the 
nucleus and the subsequent activation of its target genes involved in glycolysis and lipogenesis 
(66).  
Transcriptional regulation plays a key role in regulating hepatic lipid homeostasis under 
metabolic and inflammatory conditions. Metabolic signals, such as increased levels of FAs, 
glucose, and insulin, can regulate the activity or abundance of key transcription factors to 
modulate hepatic lipid metabolism (67). Many hepatic transcription factors have been 
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identified as prospective targets for de novo lipogenesis and fatty acids oxidation, including 
sterol regulatory element binding protein-1c (SREBP-1c) (67), retinoid X receptor (RXRα) 
(68), liver X receptor (LXRα) (69), peroxisome proliferator-activated receptors (PPARα, β, γ1, 
and γ2) (70), CAMP Responsive Element Binding Protein 3-Like 3 (CREB3L3 or CREBH) 
(71, 72), and chREBP. These factors integrate signals from various pathways and coordinate 
the activity of the metabolic machinery necessary for hepatic lipid metabolism with the supply 
of energy and fatty acids. 
 
1.9 Understanding Cyclic AMP Response Element Binding Protein H 
(CREBH) 
CREBH, A novel liver-specific cell stress sensor, has been demonstrated to be involved 
in NAFLD (73). CREBH is a basic leucine zipper transcription factor of CREB/ATF family. 
The CREB family is a group of a bZIP transcription factor in mammals consisting of 
CREB3L1, CREB3L2 CREB3L3, and CREB3L4 (74). CREB3L3 or CREBH was first 
reported to be a liver-specific transcription factor (75, 76). The entire CREB family 
transcription factor shares significant homology within their bZIP domain that mediates DNA 
binding and dimerization. They all have a transmembrane domain at the C-terminal side of the 
bZIP region. The N-terminus faces the cytoplasm while the C-terminal is anchored to the ER 
membrane into ER lumen. All the CREB3 families of the transcription factor are activated by 
a mechanism called Regulated Intramembrane Proteolysis (RIP) (77). 
It has been shown that the CREBH is richly expressed in liver hepatocytes. Low levels 
of CREBH can be detected in the pyloric stomach and small intestine tissues. Full-length 
CREBH protein is localized in the ER membrane of liver hepatocytes and bears a similarity in 
structure with an ER stress sensor, Activation Transcription Factor 6 (ATF6). Transcription of 
the  CrebH  gene is highly induced by pro-inflammatory cytokines including TNFα, IL-6, IL1β, 
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as well as bacterial endotoxin LPS. This was evident that expression and activation of CREBH 
were induced by LPS or TNFα challenge (1). 
The current model for activation of CREBH under ER stress is elucidated by Zhang et 
al (78). Under ER stress and inflammatory challenge, CREBH is released from ER membrane 
and translocate to Golgi. At Golgi, it undergoes proteolytic cleavage by S1P and S2P protease 
to release its functional, cytosolic (N-terminus) fragment that functions as a transcription 
factor. Interestingly, rather than activating the transcription of UPR genes, it activates the 
expression of acute phase inflammatory factors, C-reactive protein, serum amyloid component 
P (SAP), and serum amyloid A (SAA). Hence, it has been propose that CREBH represents a 
molecular link between ER stress and hepatic inflammation. Additionally, it has found that 
CREBH can induce expression of hepcidin, a novel liver acute-phase protein that plays a 
central regulatory role in iron homeostasis under inflammatory stress conditions (79). 
RIP can be triggered by ER stress, inflammatory stress or metabolic stress (80, 81). 
After RIP process, the cleaved CREBH N-terminal fragment then transits into the nucleus to 
function as an active bZIP transcription factor (1). 
 
 
Figure 1: Schematic model for 
CREBH location and its 
activation mechanism.  
 ER stress leads to cleavage of 
CREBH to release precursor 
CREBH that translocates to Golgi 
to undergo proteolytic cleavage 
by S1P and S2P proteases. The N-
terminal cleaved form then goes 
to the nucleus to activate 
transcription. CREBH does not 
contribute to the classical UPR 
induction but is required for the 
APR by regulating transcription 
of the CRP and SAP genes. Image adapted from Cell Press.(1) 
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Recently, we have shown that CREBH plays important roles in regulating lipid 
metabolism in the liver. Fasting condition, high-fat diet, insulin signals, or saturated fatty acids, 
such as palmitate, can activate CREBH (73). Pro-inflammatory cytokines including TNFα, IL-
6, and IL1 β, as well as bacterial endotoxin LPS, can induce CREBH cleavage in the liver in 
vivo. It has been demonstrated that administration of TNFα, IL-6 plus IL1 β, or LPS into the 
animals can induce physiological ER stress in the live (1). Upon activation, CREBH acts as a 
potent transactivator to induce expression of the genes encoding key regulators or enzymes 
involved in gluconeogenesis, lipogenesis, FA oxidation, ketogenesis, and lipolysis (71, 73). 
Notably, CREBH interacts with PPARα to synergistically activate the metabolic hormone 
FGF21 to regulate lipolysis, FA oxidation, and ketogenesis upon fasting or under an 
atherogenic high-fat (AHF) diet (71). The overall role of CREBH is to maintain energy 
homeostasis under metabolic stress. A defect in CREBH leads to non-alcoholic steatohepatitis 
(NASH) and hyperlipidemia under the AHF diet or fasting (71, 73, 82). Bioinformatics analysis 
indicated that human patients with hyperlipidemia had higher rates of CrebH gene mutations 
(82).  
 
1.10 Hypothesis, objectives, and project overview 
Invasion by pathogens can cause a variety of physiological responses in the host. These 
include various metabolic changes in local tissues. Components of bacterial cell walls are key 
molecules involved in triggering a particular metabolic responses in the host. Hyperlipidemia 
usually accompanies bacterial infection as well as inflammation (76). The association between 
the increase in TG and infection is partially due to increased in lipoprotein production as well 
as defective clearance of lipoproteins from circulation. Currently, little is known about the 
mechanism underlying the crosstalk between the body’s immune system and metabolism. My 
thesis research uncovers a mechanism behind the previously noted metabolic changes 
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associated with endotoxemia. LPS, a potent ligand of TLR4 and a major bacterial endotoxin, 
is produced during the metabolic process. Therefore, we utilized LPS stimulation as model 
endotoxin for our studies. 
In light of the central role of TLR4 in innate immunity and inflammation, a major 
hypothesis of my study is that the inflammatory pathway mediated through TLR4 is a key 
regulator of cleavage and activation of CREBH. We have hypothesized that the adaptors of 
TLR4 signaling cross-talk with CREBH and leads to CREBH cleavage and activation through 
post-translational modifications. Subsequently, TLR4 signaling pathway modulates hepatic 
lipid metabolism through activation of CREBH-mediated transcriptional program. I 
hypothesized that some of the metabolic hallmarks of endotoxemia were partially regulated by 
the TLR4-CREBH signaling axis. 
To test this hypothesis, I comprehensively evaluated the suitability of in vitro cell 
culture system as well as in vivo low-grade inflammation model. To this end, I employed 
strategies to induce typical low-grade inflammation in C57BL/6J mice by administration of 
low levels of LPS administration. The dosage of 2μg/gm body weight of mouse has been 
previously used as low dosage to understand the metabolic effects of LPS challenge on body 
glucose metabolism and mitochondrial biology (83, 84). Liver inflammatory and metabolic 
alterations in these animal models were systematically evaluated using both pathological 
parameters and biomarkers. After this evaluation, we found that intraperitoneal injection of 
LPS under normal mouse chow diet is a suitable animal model for studying endotoxemia-
induced inflammatory metabolic responses in the liver and to explain some of the key 
mechanisms underlying endotoxin-mediated modulation of hepatic metabolism. 
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Chapter 1: Defining the role of hepatocyte-specific TLR4 signaling in CREBH cleavage 
and subsequent activation. In this chapter, I investigate LPS-induced cleavage of CREBH 
protein, involvement of TLR signaling in LPS-induced CREBH cleavage, and effects of other 
stimuli on CREBH activation. I also provide new light on ambiguity associated with the 
presence of TLR4 in hepatocytes. 
 
Chapter 2: Elucidating the cross talk between TLR4 signaling pathway and activation of 
CREBH. Under this chapter, I demonstrated the molecular basis through which TLR4 
signaling interacts with CREBH transcription factor and the components of the TLR4 signaling 
pathway that are essential to mediate the cross talk. I determined the possible location of 
CREBH interaction with TLR4 signaling components under the acute endotoxin challenge. 
 
Chapter 3: Determining the post-translation modifications involved in CREBH cleavage 
and activation. I have discussed the role of ubiquitination in CREBH cleavage and activation. 
I also briefly evaluated the potential role of phosphorylation in CREBH cleavage and 
activation. 
 
Chapter 4: Determining the downstream targets of CREBH under the bacterial 
endotoxin challenges. In this chapter, I identified CREBH-target genes under endotoxin by 
gene expression analyzes, Chromatin Immunoprecipitation (ChIP) analysis, and gene 
expression reporter analysis.  
 
Chapter 5: Delineating the pathophysiological effects of CREBH deficiency on 
metabolism and inflammation. In this chapter, I determined the hepatic and serum TG levels, 
serum cholesterol (HDL, LDL, and total cholesterol) levels in CREBH knockout and wild-type 
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control mice under LPS challenge. I also evaluated the impact of CREBH deficiency in energy 
consumption, food intake, and body weight under the LPS challenge. 
Chapter 6: Conclusions and Significance 
  
 
 
 
 
 
 
 
Figure 2: Working hypothesis for TLR4 mediated cleavage of CREBH under LPS 
treatment  
Working model of our hypothesis. LPS upon binding to TLR4 receptor induce activation of 
TL4 receptor signaling pathway. Component of TLR4 signaling pathway are involved in 
direct cross talk with CREBH for its subsequent activation. PI3K-Akt axis pathway 
triggered by TLR4 receptors also plays crucial role in CREBH cleavage and activation. 
These signaling pathways leads to CREBH translocation and cleavage into active form of 
CREBH. Active CREBH translocates to nucleus inducing transcription of specific genes 
involved in response to LPS stimulation. 
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CHAPTER 1: Delineating the role of TLR4 signaling in CREBH 
cleavage and activation in hepatocytes 
 
 
Summary 
As described above, TLR4 is one of the mammalian pattern recognition receptors, 
recognizing pathogen-associated molecules and playing pivotal roles in the innate immune 
response. A recent study reported that saturated FA-mediated TLR4 signaling activation 
induces changes in expression of metabolic genes in hepatocytes (85). In addition, TLR4 
activation is also associated with insulin resistance and high-fat diet-induced obesity and 
diabetes (86).  Our previous study suggested a role for inflammatory stress in cleavage and 
activation for the CREBH hepatocytes specific transcription factor.  Intraperitoneal injection 
of LPS can cause cleavage and activation of CREBH (87). A direct effect of LPS on CREBH 
activation in hepatocytes has not been well studied.  
To address this question, we first assayed for the presence of TLR4 in hepatocytes. 
Healthy liver express low levels of TLR4 mRNA (88). Since there is ambiguity about the 
presence of TLR4 receptors in hepatocytes, we assessed whether CREBH is cleaved in primary 
hepatocytes challenged with LPS along with TLR4-specific agonist UT12 and antagonist 
RP105 (89). Under the alcoholic liver disease condition, hepatocytes and Kupffer cells have 
been shown to interact closely to induce steatosis and cirrhosis (90). We used UT12 , which 
enables us to verify the TLR4-specific effect on CREBH cleavage mechanism. I also evaluated 
the direct and indirect effects of LPS on CREBH activation in primary hepatocytes. Since LPS 
can stimulate cytokine production in Kupffer cells (resident macrophages in the liver), which 
may in turn lead to CREBH cleavage through TNFα production (indirect mechanism), I 
investigated the potential role and contribution of this indirect mechanism to CREBH 
activation in hepatocytes. I co-cultured hepatocytes and Kupffer cells to reveal the cross-talk 
between two cell types under LPS stimulation.  
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Analyzing all these aspects helps establish the system for my further mechanistic 
studies.  Meanwhile, these approaches also reveal important aspects of endotoxin-mediated 
CREBH cleavage in hepatocytes. In this chapter 1) assessed the presence of TLR4 receptors in 
primary hepatocytes, 2) confirmed the direct role for TLR4 signaling pathway in primary 
hepatocytes, 3) addressed the contribution of the indirect pathway under endotoxin challenge, 
and 4)  established the cell culture and animal model system for  our future studies. 
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Material and Methods 
 
All the chemicals used in this study were purchased from Sigma-Aldrich (St. Louis, 
MO) unless otherwise stated. Synthetic oligonucleotides were purchased from Integrated DNA 
Technologies, Inc. All animal use and procedures were approved by the Wayne State 
University Animal Care and Use Committee. 
 
Animal experiments 
 CrebH-null mice with exons 4–7 of the CrebH gene deleted were previously described 
(91).  CREBH-null and wild-type control mice on a C57Bl/6J background of approximately 3-
month-old were used for the experiments. The normal chow diet was from Harlan Laboratories. 
All the animal experiments were approved by the Wayne State University IACUC committee 
and carried out under the institutional guidelines for ethical animal use. For the LPS injection 
experiment, CREBH-null and wild-type control male mice under the normal chow diet were 
injected intraperitoneally with LPS (2 μg/gm body weight) or vehicle PBS. After 18 hr post 
injection, mice were sacrificed for tissue collection. 
 
Western blotting analysis 
Protein from liver tissues or cultured cells was solubilized by disrupting and 
homogenizing with NP40 lysis buffer (1%Nonidet P-40, 20 mM Tris-HCl, pH 7.5, 150 mM 
NaCl, 5 mM EDTA, and freshly added protease inhibitor cocktails) in the presence of the 
protease inhibitor cocktail (Roche Applied Science). After homogenization, tissue or cell lysate 
was centrifuged at a speed of 14,000g for 20 min. at 4°C. The clear supernatant was carefully 
aspired and transferred to a new microcentrifuge tube. Protein concentrations were determined 
with bicinchoninic (BCA) protein assay kit according to manufacturer’s instruction (Pierce 
Biotechnology Inc., Rockford, U.S.A.). Thirty μg of protein s were mixed with protein loading 
24 
 
 
buffer, heated at 95°C for 10 min, subjected to SDS-PAGE, and then transferred onto PVDF 
membrane. Following the washing with TBS-T buffer for 5 min, the membranes were 
incubated with 5% (w/v) non-fat milk in TBS-T buffer at room temperature for 1 hr to block 
non-specific binding. The membranes were then probed with specific primary antibodies at 
4°C overnight. The membranes were washed with 1x TBS-T for 4 times (15 min per time), 
followed by incubation with corresponding horseradish peroxidase-conjugated secondary 
antibodies at room temperature for 1 hr. After washing with 4 changes of TBS-T buffer for a 
total of 60 min, the protein bands were visualized with enhanced chemiluminescence reagents 
(Thermo Fischer, USA). Primary antibodies used including CREBH (Thermo Fischer, USA), 
GAPDH, β-Actin (Sigma Aldrich, MO, USA) 
 
Isolation and culture of mouse primary hepatocytes and Kupffer cells 
Primary hepatocytes from wild-type C57BL/6J mice were prepared as described 
previously. Briefly, in situ liver perfusion was performed with 0.02% collagenase type IV 
(Sigma Aldrich, USA) in Hank’s balanced salt solution through a portal vein at a rate of 8 
ml/min. After complete perfusion, liver cells were dispersed in DMEM medium. Cell 
suspensions were then filtered through 100 μm nylon cell strainer (BD Falcon, USA) to remove 
tissue debris and cellular aggregates. The filtrates were centrifuged at 50g for 2 min in an 
Eppendorf centrifuge 5810/R and subsequently divided into two layers, hepatocytes-enriched 
pellet and non-parenchymal cells (NPC)-enriched supernatant. Hepatocytes were collected 
after cell pellet was washed with PBS. 
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Cell culture 
Isolated primary hepatocytes were seeded in culture flasks and maintained in 
Dulbecco's Modification of Eagle's Medium (Thermo Fischer, Rockford,MA, USA) containing 
10% fetal calf serum (Thermo Fischer, Rockford,MA, USA), 100 U/ml penicillin and 100 
μg/ml streptomycin. Human hepatoma cell line Huh7 was a generous gift from Dr. Charles 
Rice Rockefeller University. Huh7 cells, mouse macrophage cell line Raw264.7, and primary 
hepatocyte Cells were incubated in an incubator at 37°C with humidified atmosphere with 5% 
CO2 and 95% air. Cells were seeded at a number of 1 million/ well of 6 well plate. Various 
treatments were performed at about 80% confluence. When the treatments were finished, cells 
were harvested by incubating with 1 ml of 0.1% trypsin/EDTA (0.02%) for 3 min to allow the 
detachment of cells. Then, pelleted cells were re-suspended in NP40 lysis buffer for protein 
analysis. 
 
Reverse transcription (RT)-PCR 
Total RNA was extracted from primary hepatocytes using TRIZol (Life Technologies, 
Gaithersburg, Md) extraction method. First-strand cDNA was synthesized from 0.5 μg of RNA 
using reverse transcriptase (SuperScript III RT; Life Technologies, Gaithersburg, Md.) and 
pool of  20 random primer (Life Technologies, Gaithersburg, Md) in 20-μl reaction mixtures, 
according to the manufacturer's instructions. The synthesized first-strand cDNA was diluted to 
a total volume of 200 μl with distilled water. An aliquot of first-strand cDNA was amplified 
by PCR master mix (Promega, Cat No: M7501) in a total volume of 50 μl including  of 2X 
super mix, primers (1μM) and 100ng template cDNA. PCR cycle consisted of denaturation at 
94°C for 1 min, annealing at 54°C for 1 min, and extension at 72°C for 0.5 min. Before the 
first cycle, an initial denaturation step of 3 min at 94°C was included, and for 30 cycles, the 
26 
 
 
PCR products were separated by electrophoresis on 2% agarose gels. The sequence of primers 
used has been listed in Appendix B. 
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Result 
LPS treatment induces CREBH cleavage, at a level comparable to ER stress and 
metabolic stress. 
CREBH cleavage and activation is induced by ER stress and metabolic stress conditions 
like fasting and high-fat diet (1, 71, 72, 92). We investigated the levels of CREBH cleavage 
and activation under LPS treatment and compared the levels of CREBH cleavage between LPS 
and previously defined stressors (71, 87). Huh7 cells infected with adenovirus expressing full-
length CREBH were treated with glucagon (fasting stress), Tunicamycine (Tm), Thapsigargin 
(Tg), and LPS for 4hr, 8hr, and 12hr. LPS significantly induced cleavage of CREBH precursor, 
at a level comparable to that of glucagon, Tm, or Tg (Fig 3A). Interestingly, LPS or glucagon 
treatment increased levels of CREBH precursor protein, compared to vehicle, Tg, or Tm 
treatment (Fig 3A). Indeed, treatment with pharmacological ER stress inducer Tm or Tg led to 
a reduction in CREBH precursor protein levels, presumably due to the translational attenuation 
mediated through the classic UPR signaling (Fig3A). These results help us to evaluate the effect 
of LPS on CREBH activation in comparison to the effects of the other defined stressors.  
 
 
 
 
 
 
 
Figure 3 CREBH cleavage and 
activation with inflammatory, 
metabolic and ER stress 
inducers 
 (A) Huh7 cells were infected with 
adenovirus expressing human full-
length CREBH for 72 hr, and then 
treated with LPS (1μg/ml), 
tunicamycin (5μg/ml), glucagon 
(500nM/ml), or thapsigargin 
(10μM/ml) the non-transfected cells 
were included as negative controls. 
Western blot analysis was performed 
to detect CREBH cleavage by using 
CREBH polyclonal antibodies. 
Levels of GAPDH were determined 
as loading control.  
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C57/BL6 mice upon LPS injection displayed low-grade inflammation and CREBH 
cleavage. 
As mentioned in the methods, the animals were injected intraperitoneally with LPS 
(2µg/gm of body weight) for inducing acute endotoxemia. This dosage of LPS has been defined 
as low dosage of endotoxins (84) and has been implicated in acute phase response associated 
with LPS (93, 94).  Upon LPS challenge, levels of both CREBH precursor and activated form 
of CREBH proteins were elevated in the liver of C57/BL6 mice (Fig 4A). 
 
 
 
 
 
Figure 4. CREBH cleavage and activation with inflammatory stress inducers 
 (A) Western blot analysis of CREBH cleavage in the liver tissue samples from wild-type mice under the 
normal chow (NC) injected with either PBS (vehicle control) or LPS (2 μg/gm body weight) for 18 hr. 
Western blot analysis was performed to detect CREBH cleavage by using CREBH polyclonal antibodies 
with GAPDH as loading control. 
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TLR4 receptors are present in a low amount in primary hepatocytes. 
Because of uncertainty surrounding presence of TLR4 on primary hepatocytes, I 
evaluated the relative abundance of the TLR4 receptor mRNA, in comparision to other 
common TLR receptors, including TLR2 and TLR3. Semi-quantitative RT-PCR analysis of 
total mRNA from primary hepatocytes showed that TLR4 mRNA are present on mouse 
hepatocytes, although in low levels (Fig 4A). The relative abundance of TLR4 on primary 
hepatocytes, compared to RAW cells, is low, nonetheless our studies confirmed the low-level 
presence of TLR4 mRNA in primary hepatocytes, in accordance with some of the previous 
literature (95).  
 
 
 
 
 
 
 
 
 
Figure 5. TLR expression levels in primary hepatocytes. 
(A) Semi-quantitative RT-PCR analysis of the expression levels of mRNAs for TLR2, TLR3, and TLR4 in 
primary hepatocytes isolated from wild type mice. β-actin mRNA was used as a loading control. 
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TLR4 signaling in primary hepatocytes induces cleavage of CREBH transcription 
factor. 
To determine the involvement of TLR4 signaling in CREBH cleavage, I examined 
CREBH cleavage in primary hepatocyte in the presence of specific TLR4 agonist and 
antagonist. In response to LPS treatment, CREBH cleavage was increased in primary 
hepatocytes isolated from C57/BL6 mice (Fig 5A). Treatment of UT12, a specific agonist for 
TLR4 (96), led to a modest increase in CREBH cleavage, compared to the PBS treatment 
control. As a control, treatment with RP105, a specific inhibitor of TLR4 signaling  (96), caused 
a marginal change in CREBH cleavage in primary hepatocytes, compared to the PBS treatment 
(Fig 6A). 
Since liver-resident macrophages, Kupffer cells, are the major inflammatory resource 
in the liver, I next evaluated the potential involvement of Kupffer cells-mediated cytokine 
production in CREBH cleavage in primary hepatocytes. Primary hepatocytes isolated from 
wild-type C57/BL6 mice were subjected to the treatment with conditioned medium from mouse 
macrophage cell line RAW264.7 treated with LPS (100ng/ml).  Condition medium treatment 
resulted in increased CREBH cleavage, compares to the primary hepatocytes directly treated 
with LPS. However, this increase was not tremendous. Hepatocytes directly treated with LPS, 
as well as hepatocytes treated with LPS-stimulated conditioned medium from macrophages 
displayed increased in CREBH expression and cleavage (Fig 6B).  
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Figure 6. Activation and cleavage of CREBH is a direct effect of LPS through TLR4 signaling in 
hepatocytes.  
Primary hepatocytes isolated from wild-type mice were treated with LPS (100ng/ml) with condition 
medium from Raw cells treated with PBS or LPS (100ng/ml) for 4hr (B) and (A) UT12 (5μg/ml), RP105 
(5μg/ml) for 4 hr. Western blot analysis was performed to detect endogenous CREBH cleavage using a 
CREBH polyclonal antibodies with GAPDH as loading control. 
. 
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Discussion 
 
The liver is the primary metabolic and detoxification organ in the body. Upon bacterial 
or viral infection, the liver plays an important role in mounting a defense response to pathogens 
(97). Liver immune cells and hepatocytes produce both inflammatory cytokines and 
chemokines as well as acute phase response proteins. Mounting of such response not only 
remove pathogens but also influence the liver homeostasis. A consensus opinion is that the 
response of hepatocytes to LPS is complicated, because it involves cell to cell interactions 
between hepatocytes, Kupffer cells, and stellate cells (98). Previous studies suggested that 
hepatocytes can respond independently to LPS (99). Accordingly, we undertook the present 
study to assess the LPS-responsive pathway in hepatocytes. We demonstrated that hepatocytes 
expressed low levels of transcripts for TLR4, suggesting the existence of TLR4 signaling in 
hepatocytes.  
Studies over the past few years indicated that hepatocytes can respond directly to 
microbial products. The effect of LPS In vivo on hepatic function is also well known (100). 
LPS increases liver mass and hepatocyte volume, as well as modulating the synthesis of acute-
phase proteins through the release of cytokines (TNFα and IL-6) (101). We showed that not 
only TLR4 are present on hepatocytes but also that TLR4 signaling is actively involved in 
cleavage and activation of CREBH transcription factor. Kupffer cells also play a significant 
role in CREBH expression, cleavage, and activation, but hepatocytes also respond to LPS 
response. Inhibition of theTLR4 response signaling lead to less CREBH cleavage under  LPS 
stress conditions. My study suggested that hepatocytes can directly respond to LPS challenge 
in cleavage and activating CREBH. In vivo microenvironment, signaling from Kupffer cells 
can also contribute to CREBH cleavage and activation in hepatocytes, possibly through the 
production of pro-inflammatory cytokines, such as TNFα and IL-6. Indeed, this is consistent 
with our previous study showing that TNFα and IL-6 can induce CREBH cleavage (1). 
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Nevertheless, the direct effect of LPS on hepatocytes in triggering CREBH cleavage was 
significant, suggesting the inflammatory pathway in hepatocytes plays a major role in CREBH 
activation upon bacterial endotoxin challenge. 
In summary, the studies described in this chapter indicated a prominent role of TLR4 
on hepatocytes in CREBH cleavage and activation. The experimental results also confirmed 
the participation of Kupffer cells in CREBH cleavage and activation in the liver in vivo. 
Involvement of TLR4 signaling-mediated CREBH cleavage and activation laid a foundation 
for further study on the proposed role of endotoxin in modulating hepatic metabolism through 
activation of CREBH. 
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CHAPTER 2:  TRAF6-mediated ubiquitination of CREBH 
promotes CREBH cleavage and activation 
 
Summary 
 
As we showed previously, LPS or TNFα stimulation triggered CREBH cleavage in 
hepatocytes. Additionally, treatment with UT12, a TLR4-MD2 agonist, can also induce 
CREBH cleavage. Therefore, the component of TLR4 signaling likely plays a crucial role in 
CREBH cleavage and activation. TNFα- or LPS- induced inflammatory signaling is mediated 
through TNFα receptor-associated factors (TRAF’s). Member of TRAFs are a family of 
conserved adaptor proteins that, through their association with cytoplasmic domains of 
different receptors, mediate the activation of various intracellular signaling pathways. TRAF 
family of adaptor proteins shares considerable homology in their structures. While the TRAF 
factors, TRAF2, and TRAF6, are ubiquitou, TRAF6 functions as a key mediator in TLR 
signaling. Hence, I hypothesized that TRAF6 may interact with CREBH to regulate CREBH 
cleavage and activation under LPS challenge. 
Distinct from other TRAFs, TRAF6 is an E3 ubiquitin ligase, and through association 
with the dimeric ubiquitin-conjugating enzyme Ubc13/Uev1A, it catalyzes lysine 63 (K63)-
linked polyubiquitination of several target proteins. Recent studies suggested that TRAF6 
functions as a key regulator in multiple signaling pathways, such as NF-κB, mitogen-activated 
protein kinase (MAPK), and phosphatidylinositol 3-kinase (PI3K)/Akt, in response to various 
cytokines and microbial products (102). Although it remains a mystery if  the E3 ubiquitin 
ligase activity of TRAF6 is crucial for its  participation and function in signaling pathway, 
recent studies have shown that TRAF6 functions as a central regulator in multiple signaling 
pathways, such as NF-κB, mitogen-activated protein kinase, and phosphatidylinositol 3-
kinase/Akt, in response to various cytokines and microbial products (103). In addition to its 
35 
 
 
association with cytoplasmic domains of various cell surface receptors, such as Toll-like 
receptors and the interleukin-1 receptor (IL-1R), TRAF6 has also been found to interact with 
multiple components of the ubiquitin proteosomal system (UPS) and involved in 
autophagosome formation in skeletal muscles (103).  
Under TLR4 signaling pathway, TRAF6 undergoes self-polyubiquitination  and helps 
in docking of different downstream kinases at the  ternary complex of Myd88-IRAK4-TRAF6. 
It has been shown that TRAF6 is involved in insulin signaling and phosphorylation of Akt. Our 
group recently demonstrated that TRAF6 interacts with IRE1α, an ER-anchored protein 
mediating unfolded protein response (UPR). Interaction of TRAF6 with IRE1α induces IRE1α 
ubiquitination and prevents its dephosphorylation by the phosphatase PP2A.(104). 
Protein ubiquitination is an important PTM that regulates various biological functions. 
Although most of ubiquitination processes lead to protein degradation, a particular type of 
ubiquitination, namely the lysin 63 (K63)-lined ubiquitination, is essential for signaling 
activation and protein trafficking. It has been demonstrated that K63-linked auto ubiquitination 
of TRAF6 is a process essential to its regulatory role in starvation-induced autophagy (105). 
In this chapter, my studies confirmed that TRAF6 functionally interacts with CREBH. 
For the first time, my results demonstrated that TRAF6 positively regulates the activation of 
the TLR4-CREBH signaling pathway by binding to CREBH, a novel mechanism by which an 
ubiquitin E3 ligase promotes CREBH cleavage and subsequent activation. 
 
 
Materials and Methods 
 
Animal experiments 
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CrebH null and wild-type control mice on a C57Bl/6J background of approximately 3-
month-old were used for the experiments. The Myd88-null mice were from Dr. Ashok Kumar 
at Kresge Eye Institute, Wayne State University. All the animal experiments were approved by 
the Wayne State University IACUC committee and carried out under the institutional 
guidelines for ethical animal use. The intraperitoneal administration of LPS was carried out as 
described previously in the Material and Methods of Chapter 1. 
 
Cells and reagents 
Human endothelial kidney (HEK) 293T cells were maintained in Dulbecco's 
Modification of Eagle's Medium (Thermo Fischer, Rockford,MA, USA) containing 10% fetal 
calf serum (Thermo Fischer, Rockford,MA, USA). Transfection in HEK 293T cells was 
performed with Lipofectamine™ 2000 protocol (Invitrogen, Grand Island, NE, USA). 
Plasmids expressing CREBH and its truncated mutants were generated by PCR using linker 
primers and sub-cloned into a pCMV-Flag vector (Sigma-Aldrich, St. Louis, MO, USA). Myc-
tagged TRAF6 expression plasmid and its C70A mutant were used as previously reported 
(Yang et al, 2009). The truncated mutants were generated by PCR with linker primers followed 
by sub-cloning into a pCMV-Myc vector (Invitrogen, Grand Island, NE, USA). LPS was 
purchased from Sigma-Aldrich.  
 
 
 
 
 
Transfection, co-immunoprecipitation, and Western blotting analysis 
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Transient transfection of HEK293T cells was performed by using Lipofectamine 2000 
(Invitrogen, Grand Island, NE, USA) or Transit 2020 (Mirus Biotech, NJ, USA) according to 
the manufacturer’s instructions. 24 hr after transfection, cells were lysed in NP-40 lysis buffer 
(1%Nonidet P-40, 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM EDTA, and freshly added 
protease inhibitor cocktails). For co-immunoprecipitation, cell lysates were incubated with an 
antibody (1 μg) for overnight at 40C, followed by the addition of 30μl recombinant protein G-
Sepharose beads  (Invitrogen, Grand Island, NE, USA) for 4 hr at room temperature. For co-
immunoprecipitation with anti-Flag pull down, cell lysates were incubated with M2 flag 
agarose beads (Sigma-Aldrich, St. Louis, MO, USA) overnight at 40C. Immunoprecipitates 
were washed four times with NP-40 lysis buffer and boiled in 40 μL of 2.5× Laemmli buffer. 
Samples were subjected to 10% or 12% SDS-PAGE analysis and electrotransferred onto 
nitrocellulose membranes (0.45μM; EMD Millipore). Membranes were probed with the 
indicated primary antibodies, followed by horseradish peroxidase-conjugated secondary 
antibodies. Membranes were then washed and visualized with an enhanced chemiluminescence 
detection system (Bio-Rad, Hercules, CA,USA). When necessary, membranes were stripped 
by incubation in stripping buffer (Thermo Fischer, Rockford, MA, USA), washed, and then re-
probed with other antibodies. For IP-Western blot analysis, total protein lysates from in vitro 
cultured lysate or were immune-precipitated with anti-FlagM2 antibody beads (Sigma 
Aldrich), followed by Western blot analysis using the anti-Flag (Sigma-Aldrich, St. Louis, MO, 
USA), anti-myc (EMD Millipore) antibody to detect. Antibodies used in this chapter include 
polyclonal CREBH Polyclonal anti-CREBH antibody was raised by immunizing rabbits with 
a mouse CREBH protein fragment spanning N-terminal amino acids 75–250 of mouse CREBH 
protein,  TRAF6 (Santa Cruz Biotech, CA,USA), and Myd88 (Cell signaling technologies, CA 
USA) antibodies. 
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Immunofluorescence staining 
Immunofluorescence analysis of protein subcellular localization was performed as 
described. Briefly, Huh7 cells transfected with the plasmid vector expressing full-length 
CREBH and myc- tagged TRAF6. At 48 hr after the transfection, the cells were fixed with 4% 
(v/v) paraformaldehyde (Sigma, St. Louis, MO) for 10 minutes at room temperature followed 
by cell permeabilization with 0.5% Triton-X 100 (Fisher) for 2 min. Cells were blocked with 
5% horse serum overnight at 4°C, followed by incubation with a 1:1000 dilution of an 
appropriate primary antibody, anti-Flag (Sigma Aldrich) or anti-Myc (EMD Millipore), for 1 
hr at room temperature. After antibody incubation, the cells were washed by washing buffer 
(0.5% Triton in PBS) for 5 min for a total of 3 times, followed by treatment with the secondary 
antibodies, anti-rabbit Alexa545 (Abcam, MA, USA) or anti-mouse Alexa 695 (Abcam, MA, 
USA). Images were analyzed using Zeiss LSM Alpha Imager Browser v4.0 software. 
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Results 
 
TLR signaling is involved in the interaction of CREBH and TRAF6 in mouse liver tissue 
under LPS challenge. 
We utilized Myd88-null mice to elucidate the molecular mechanism underlying TLR4 
signaling-mediated CREBH cleavage and activation. Myd88 is an upstream adaptor protein 
that is involved in TLR4 signaling pathway (Fig 7B). We first analyzed the responsiveness of 
MyD88 null mice to LPS challenge. MyD88 null and wild-type control mice were 
intraperitoneally injected with low dose of LPS (2 μg/gm body weight). After the challenge, 
the Myd88 null and wild-type control mice had comparable levels of weight loss and food 
intake.  The levels of cleaved CREBH in the wild-type control mice were comparable to those 
in Myd88 null mice in the absence of LPS treatment (Fig 7A).  However, less CREBH cleavage 
was observed in Myd88 null livers upon LPS challenge. We further investigated the mechanism 
underlying the reduced amounts of cleaved CREBH protein. We examined the interaction 
between endogenous CREBH and TRAF6 in the liver tissues of wild-type control and Myd88 
null mice upon LPS challenge. The interaction between endogenous CREBH and TRAF6 was 
barely detected in the Myd88 null mouse livers under the LPS challenge (Fig 7A).  Taken 
together, these results suggested that the absence of MyD88, a key component of TLR4 
signaling, diminished the effect of LPS in activating CREBH in the liver. 
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Figure 7. Intact TLR4 signaling is necessary for CREBH cleavage and for its interaction with 
TRAF6 
(A) Immunoprecipitation and Western blot analysis of CREBH, TRAF6 and Myd88 protein levels in 
liver tissue samples from wild-type mice  and Myd88 null mice under the normal chow (NC) injected 
with either PBS (vehicle control) or LPS (2 μg/gm body weight). Top panel shows the interaction 
between CREBH and TRAF6 in wild type and Myd88 null mice injected with LPS. CREBH protein 
in liver lysates was immunoprecipitated with the polyclonal CREBH antibody. (B) Schematic diagram 
shows the role of Myd88 adaptor molecule in TLR4 signaling pathway. 
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MATH domain of TRAF6 interacts with the linker domain of CREBH protein. 
To further delineate the molecular mechanism by which TLR4 signaling regulates 
CREBH cleavage, we investigated the molecular basis underlying the interaction between 
TRAF6 and CREBH. First, we tested the interaction between CREBH and TRAF6 in the 
presence or absence of endotoxin stimuli (Fig 7A). Immunoprecipitation (IP)–Western blot 
analysis with the HEK293T cells expressing exogenous CREBH and TRAF6 showed that 
CREBH protein can interact with TRAF6 (Fig 8B). Further, we demonstrated the interaction 
between endogenous TRAF6 and CREBH in LPS-injected mouse liver. Importantly, LPS 
stimulation significantly enhanced TRAF6-CREBH interaction in mouse liver. 
To gain insights into the mechanism underlying CREBH and TRAF6 interaction, we 
generated truncated mutations for both TRAF6 and CREBH proteins to map their interaction 
domains. IP–Western blot analysis revealed that the C‐terminal meprin‐associated TRAF 
homology (MATH) domain of TRAF6 is required for its interaction with CREBH (Fig 8B). 
Moreover, we defined that the linker region between the transmembrane domain and the kinase 
domain of CREBH is required for CREBH interaction with TRAF6 (Fig 9B). Importantly, 
deletion of E3 ligase domain of TRAF6 protein significantly affects the cleavage of CREBH 
protein, as revealed by Western blot analysis (Fig 8B). Interaction of TRAF6 (MATH domain 
mutant) with CREBH was correlated with a reduction in CREBH cleavage, these results 
suggest that CREBH and TRAF6 interactions may contribute to the CREBH activation process 
(Fig 8B). 
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Figure 8. MATH domain of TRAF6 interacts with CREBH for its cleavage and activation. 
(A) Schematic representation of TRAF6 and its truncated mutants. TRAF6 carries an N-terminal RING 
finger domain and a C-terminal MATH domain (top panel). FL: full-length structure, N: N-terminal RING 
finger domain, TF: trans-membrane domain, C: C-terminal MATH domain. (B) IP –western blot analysis 
showing CREBH and TRAF6 interaction. Flag-tagged CREBH and Myc-tagged TRAF6 plasmids were 
co-transfected into HEK293T cells. CREBH protein in the lysates of transfected cells was 
immunoprecipitated with an anti-Flag antibody. The bound TRAF6 was determined by western blotting 
using an anti-Myc antibody, The expression of the full-length and truncated TRAF6 protein was indicated 
by the symbol ‘*'. GAPDH was detected as a loading control. 
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Figure 9.  Linker domain of CREBH interacts with TRAF6 for its cleavage and activation. 
(A) Schematic representation of CREBH and its truncated mutants. CREBH carries an N-terminal 
domain, B-Zip domain, and a C-terminal region (top panel). FL: full-length structure; ∆ N, N-terminal 
deletion mutant; ∆ C, C-terminal deletion mutant. (B) IP-Western blotting showing CREBH and 
TRAF6 interaction. Flag-tagged CREBH and Myc-tagged TRAF6 plasmids were co-transfected into 
HEK293T cells. CREBH protein in the lysates of transfected cells was immunoprecipitated with an 
anti-Flag antibody. The bound TRAF6 was determined by western blotting using an anti-myc 
antibody. 
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CREBH and TRAF6 interactions take place at ER membrane. 
To further investigate and confirm the interaction between CREBH and TRAF6, we 
examined the subcellular distribution of the full-length CREBH and TRAF6 protein via 
immunofluorescence analysis. To elucidate and confirm the interaction, we transiently 
overexpress full-length CREBH and wild-type TRAF6 protein in Huh7 cells. As shown in Fig 
10A, the full-length CREBH protein is localized in the ER membrane. We confirmed the ER 
localization of CREBH by co-staining the cells with PDI (Fig 10C), an ER retention marker, 
as the green fluorescence of CREBH co-localized with red fluorescence of PDI. Co-localization 
of CREBH and TRAF6 was also confirmed with Huh7 cells transiently expressing full-length 
CREBH and TRAF6 proteins (Fig 10D).  These results confirmed the interaction between the 
ER anchored full-length CREBH protein and TRAF6 at ER membrane of the cells. 
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A B
C D
Figure 10.  Interaction between CREBH and TRAF6 takes place at ER membrane. 
Immunofluorescence analysis of Huh7 cells co-transfected with full-length Flag tagged human 
CREBH and Myc tagged TRAF6. (A) CREBH only (B) TRAF6 only (C) CREBH + PDI (ER marker) 
(D) Co-transfection showing CREBH and TRAF6 overlaps in Huh7 cells stained with anti-flag FITC 
(CREBH) and anti-myc ALEXA (TRAF6). Images were analyzed using Zeiss LSM Alpha Imager 
Browser v4.0 software (Zeiss). Magnification: 600X 
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Discussion 
 
This chapter demonstrated one of the most important aspects of our hypothesis, the 
interface of innate immunity and metabolism through the interaction between CREBH and 
TRAF6. This provided important insights into the molecular mechanisms underlying CREBH 
cleavage and activation under LPS treatment. 
First, my study indicated that TRAF6 is essential for CREBH cleavage under LPS 
challenge. Co-expression of TRAF6 functional mutants (TRAF6 DC, DN, or Math domain 
deletion) with full-length CREBH significantly decreased CREBH cleavage, compared to co-
expression of wild-type TRAF6 with full-length CREBH (Fig 8B). Our finding also 
demonstrated that TRAF6 interacts with CREBH through its MATH domain of TRAF6 and 
linker domain of CREBH. Note that without the overexpression of TRAF6 in the cell culture 
system, the cells still exhibited CREBH cleavage and activation, which might be contributed 
by endogenous TRAF6 molecules. Additionally, ectopic expression of CREBH and TRAF6 
can induce cell stress that stimulates the CREBH-TRAF6 interaction without the TLR4 
stimulation. It has been reported that MATH domain of TRAF6 is involved in interacting with 
upstream kinases, as well as adaptor molecules, to transmit the signals (106). TLR4 signaling 
needs to be intact, a decrease in interaction between CREBH and TRAF6 was observed in 
Myd88 null mice. Myd88 null mice also exhibited lower levels of CREBH precursor proteins, 
in part due to the role of inflammatory signaling in the up-regulating expression of CREBH. 
Deletion of the E3 ligase RING domain of TRAF6, led to less CREBH cleavage, indicating a 
role of E3 ligase activity of TRAF6 in CREBH cleavage and activation. There are reports 
indicating the role of TRAF6 as an E3 ligase in insulin signaling and inflammatory responses 
(107, 108). The TRAF6 mutation study leads us to think about the potential of ubiquitination 
mechanism being involved in CREBH activation, as the deletion of MATH domain, where the 
E3 ligase activity resides, led to decreased CREBH cleavage (Fig 8B). Additionally, the 
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CREBH mutants exhibited lower levels of interaction between CREBH and TRAF6 due to the 
deletion of the linker region between b-Zip and transmembrane domain. The ΔN mutant 
displayed elevated levels of interaction due to its exposed b-Zip and linker domain of protein 
compared to WT and the ΔC mutant. 
Immunofluorescence microscopic analysis revealed the ER membrane location for the 
interaction of CREBH and TRAF6. My study confirmed that TRAF6 is relocated to the ER 
membrane for the interaction with full-length CREBH. This is consistent with a report 
suggesting that TRAF6 translocate and interacts with target molecules for the post-translational 
modification activities of Akt (107). In summary, this chapter revealed the mechanism and 
location of interaction between TLR4 signaling and CREBH, an important event for CREBH 
cleavage and activation under LPS challenge.  
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CHAPTER 3: Posttranslational ubiquitination of CREBH 
is necessary for CREBH cleavage and activation 
 
Summary 
 
Post-translational modifications (PTMs) can restrict the inflated number of 
transcription factors, expanding the functional repertoire of genetic regulatory elements to 
cover the diverse metabolic requirements (109). Transcription factors are subjected to protein 
turnover and targeted for degradation by the ubiquitin-proteasome system. Increasing 
evidences  pointed towards the close relation between the ubiquitin proteasomal degradation 
system and transcriptional activation (110). Protein sequences are associated with proteolysis 
of some activators overlap with their transcriptional activation domains and that components 
of the proteasome can be recruited to gene promoters through interactions with transcriptional 
regulators. It was demonstrated that ubiquitination can potentially enhance the activity of 
specific transcription factors (109). For example, ranscriptionally active forms of SREBPs are 
degraded by the proteasome in an ubiquitination-dependent manner (111). It has been 
suggested that nuclear SREBP molecules are, at least in part, ubiquitinated and degraded as a 
functional consequence of their transcriptional activity. However, the mechanistic link between 
activation of transcription factors and their degradation remains elusive. 
Protein turnover in the cells is controlled by the rate of protein synthesis and the rate of 
protein degradation. There are two major paths of protein degradation: the first is ubiquitin-
mediated proteasome pathway, and the other one is lysosomal degradation.  Ubiquitin is a 
small, but highly conserved protein consists 76 amino acids. To mark a protein for degradation, 
a ubiquitin tag is ligated to the substrate protein. Ubiquitin tagging is  carried out by the 
sequential action of three enzymes: E1, a ubiquitin-activating enzyme; E2, a ubiquitin-
conjugating enzyme; and E3, a ubiquitin-protein ligase. The ubiquitinated proteins typically 
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contain multiple chains of branched ubiquitin molecules that enable recognition by the 26S 
proteasome, which degradesof the ubiquitinated protein into small peptides (112). 
In this chapter, I investigated the role of ubiquitination modifications, mediated through 
TRAF6, in CREBH cleavage and activation. Using molecular and cellular biology approaches, 
I demonstrated that the interaction between CREBH and TRAF6, as discussed in chapter 2, 
promotes CREBH ubiquitination. Additionally, I also evaluated the potential roles of 
phosphorylation and kinases in CREBH cleavage. 
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Materials and Methods 
 
Cells and reagents 
Human endothelial kidney (HEK) 293T cells were maintained in Dulbecco's Modification of 
Eagle's Medium (Thermo Fischer, Rockford,MA, USA) containing 10% fetal calf serum 
(Thermo Fischer, Rockford,MA, USA). Transfection in HEK 293T cells was performed with 
Lipofectamine™ 2000 protocol (Invitrogen, Grand Island, NE, USA). Myc-tagged TRAF6 
expression plasmid and its C70A mutant were as reported (Yang et al., 2009). HA-tagged 
ubiquitin plasmids K33 only (K33O), K48 only (K48O), K63 only (K63O), K33, K48, and 
K63 mutants (K33R, K48R, K63R) were from Dr. Fei Sun, Department of Physiology Wayne 
State University . The resources of antibodies were: Flag, β-actin, and Tubulin from Sigma-
Aldrich (St.Loius, MO, USA); c-Myc and HA, TRAF6 were from Santa Cruz Biotech (CA, 
USA). Huh-7  cells  were   maintained  in  DMEM/High  Glucose  media  containing  100  
units/ml  penicillin,  100 μg/ml streptomycin, and 10%  fetal bovine serum. The cells at about 
60% confluence were infected with adenovirus-expressing full-length CREBH. At 72hr post 
infection, cells were treated with LPS for 4 hr, and harvested for IP-Western blot analysis. 
Okadaic acid was purchased from Sigma-Aldrich, Lys294002 was from Cell Signaling 
technology, and lithium chloride was purcahsed from Fisher Scientific. 
 
Transfection, co-immunoprecipitation and western blotting analysis 
Transient transfection of HEK293T cells as well as immunoprecipitation of cell culture 
lysates were carried out with Flag-tagged M2 beads from Sigma-Aldrich, MO, USA as 
described previously. Western blot analysis  was carried out with anti-HA, anti-CREBH, and  
anti-TRAF6 (Santa Cruz Biotech, CA , USA). 
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Cell fractionation and nuclei isolation for cell culture  
Transfected HEK293T cells  were collected at 80-90% confluence. Isolation of nuclei 
was achieved by using the hypotonic/Nonidet P-40 lysis method (113).  Briefly, cultures were 
rinsed twice with ice-cold PBS and collected with cell scrapers. Cells and were suspended in 
0.5 ml of hypotonic/Nonidet P-40 buffer (10 mM Tris, pH 7.4, 10 mM NaCl, 3 mM MgCl2, 
0.5% Nonidet P-40) and incubated on ice for 5 min. After centrifuging at 500g for 5 min, 
nuclear pellets were washed twice with 0.5 ml of hypotonic/Nonidet P-40 buffer. The 
morphological integrity of isolated nuclei (> 90%) was assessed by DAPI staining under 
immunofluorescence microscopy at 100X. The purity of subcellular fractions was verified by 
immunoblotting with antibodies specific for markers of cytosolic and nuclear fractions. 
Cycloheximide half-life experiment 
Huh7 cells were infected with the adenovirus expressing full-length human CREBH for 
48hr. After 48hr, cells were treated with LPS (1μg/ml) for 4hr. Aftert LPS treatment, the cells 
were rinsed with warm PBS twice followed by treatment with media containing cycloheximide 
(100 μM/ml) purchased from Abcam (MA,USA). Cells were collected at 0, 30, 60, 90, and 120 
min after the cycloheximide treatment. 
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Results 
 
TRAF6 mediates the ubiquitination of CREBH upon LPS stimulation. 
We determined the molecular basis by which TRAF6 regulates CREBH cleavage and 
subsequent activation of CREBH. We recently showed that TRAF6 interacts with an ER 
anchored signal transducer IRE1α in macrophages (104). Interaction between IRE1α and 
TRAF6 induces ubiquitination of IRE1α, thereby allowing the phosphorylation and subsequent 
endonuclease activity of IRE1α.  Since CREBH is an ER anchored stress associated protein 
similar to IRE1α, we hypothesized that the interaction between CREBH and TRAF6 may 
induce CREBH ubiquitination event and subsequently contribute to CREBH cleavage and 
activation. This hypothesis is supported by the truncated mutant studies, where the RING 
domain deletion in TRAF6 decreased the cleaved form of CREBH protein (Fig 8B). Through 
IP-Western blot analysis, we demonstrated that upon LPS treatment CREBH undergoes 
ubiquitination (Fig 11B). This was further confirmed by the observation that CREBH 
undergoes ubiquitination in the livers of mice challenged with LPS (Fig 12A). Furthermore, 
ubiquitination of CREBH in Huh7 cells transiently expressing Flag-tagged CREBH was 
markedly increased in response to LPS treatment. However, in HEK 293T cells, the presence 
of the E3 ligase catalytic-inactive C70A mutant of TRAF6 failed to induce CREBH cleavage 
(Fig 12B). These results indicate that the E3 ligase ubiquitin activity of TRAF6 is required for 
CREBH ubiquitination and subsequent cleavage. 
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Figure 11. LPS treatment induces CREBH ubiquitination  
(A) Western blot analysis showing protein levels of CREBH in Huh7 cells infected with 
adenovirus expressing human full-length CREBH for 72 hr.  Post 72 hr. cells were treated 
with LPS (1μg/ml) for 4hr. (B) CREBH ubiquitination was determined by 
immunoprecipitation using the anti-Flag antibody and western blotting using the anti-Ub 
antibody. Huh7 cells infected with adenovirus were pooled together to analyses CREBH 
ubiquitination. 
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Figure 12.  TRAF6 is an E3 ligase inducing CREBH ubiquitination upon LPS treatment 
(A) Western blot analysis showing CREBH ubiquitination in mouse liver injected with either 
PBS or LPS (2μg/ml) for 18 hr. CREBH ubiquitination was determined by immunoprecipitation 
using the anti-Ub antibody and Western blotting using the anti-CREBH polyclonal antibody. Last 
2 lane represent CREBH immunoprecipitation with  HA antibodies as controls. (B) HEK293T 
cells were co-transfected with CREBH, TRAF6, and TRAF7 C70A expression plasmids. Levels 
of CREBH protein were analyzed by Western blot analysis using CREBH polyclonal antibodies, 
and GAPDH as loading control. 
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TRAF6 promotes K63-linked ubiquitination of CREBH. 
E3 ubiquitin ligases are known to promote ubiquitination of their binding proteins. 
TRAF6 often catalyzes K63-linked polyubiquitin conjugation onto its substrates. To 
characterize TRAF6-mediated ubiquitination of CREBH, we co-expressed CREBH with a 
mutant ubiquitin isoform that carries a single lysine residue at position 63 (K63O) or 48 (K48O) 
or 33 (K33O) in HEK293T cells. K63O and K48O ubiquitin mutants carry a single lysine 
residue, residues 33, 48 and 63, respectively, which allows us to determine the topology of 
polyubiquitin chains. When Ub/K63O mutant is expressed, CREBH ubiquitination was 
detected (Fig 13A). In contrast, when the Ub/K48O mutant was co-transfected, only a low 
levels of CREBH ubiquitination were detected (Fig 13A). Surprisingly, K33O mutant also 
displayed a comparable level of ubiquitination of CREBH. To further delineate the type of 
polyubiquitination type occurring on CREBH, we used different ubiquitination mutant that 
won’t allow a particular type of ubiquitination. To investigate this, we overexpressed K33R, 
K48R and K63R Ub mutants in HEK293T cells along with transient overexpression of 
CREBH. Based on this approach, we demonstrated that K63R mutant failed to mediate CREBH 
ubiquitination while expression of K48R led to a comparable level of CREBH ubiquitination 
(Fig 13A). To solve the conundrum of K33, we observed that expression of K33R led to an 
elevated level of CREBH ubiquitination, compared to expression of K33O mutant (Fig 
13A).  Therefore, the poly-ubiquitin chain conjugated to CREBH protein requires the lysine 
residue 63 (K63), but not the K48, indicating that TRAF6 catalyzes K63-linked, but not K48-
linked polyubiquitination of CREBH. The weak K33-linked ubiquitination might have been 
catalyzed by other endogenous E3 ubiquitin ligases or a time dependent CREBH ubiquitination 
may be involved. 
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Figure 13. CREBH undergoes TRAF6 mediated K63 polyubiquitination upon interaction
A) Western blot analysis of K63-linked ubiquitination of CREBH. HEK 293 T cells were 
co-transfected with Flag-tagged human full-length CREBH, TRAF6, and specific ubiquitin 
expression plasmids, including K33 only (K33O), K63 only (K63O), K48 only (K48O), K33 
mutant (K33R), K48 mutant (K48R), and K63 mutant (K63R). Ubiquitination was 
determined by immunoprecipitation using the anti-Flag antibody and Western blotting using 
the anti-HA antibody. Total lysate was detected for CREBH using polyclonal CREBH 
antibodies. Level of GAPDH was used as loading control.  
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LPS treatment induces TRAF6 mediated K63 ubiquitination that increase the stability of 
CREBH protein. 
K48-linked polyubiquitination usually mediates protein degradation, whereas K63-
linked polyubiquitination regulates the activation and functions of target proteins (112). As 
TRAF6 enhances K63-linked polyubiquitination of CREBH, we tested whether TRAF6-
mediated ubiquitination is involved in CREBH protein stability. As shown in Fig 14A, the 
stability of CREBH under the LPS treatment is enhanced at the early time points, from 30 to 
60 min after the cycloheximide treatment, compared to the PBS treatment. However, at the late 
time points, from 90 to 120 min after the cycloheximide treatment, CREBH protein in the LPS-
stimulated cells was quickly degraded (Fig 14A). Importantly, at the early time window after 
the cycloheximide treatment (0, 30, and 60 min), the levels of cleaved/activated CREBH 
protein in the LPS-treated cells were significantly higher than those in PBS-treated cells (Fig 
14A). These data suggested that LPS treatment may stabilize CREBH precursor, possibly 
through K63-linked ubiquitination, and lead to production of cleaved/activated CREBH at the 
early time points. 
Since TLR stimulation enhances CREBH andTRAF6 interaction, we asked whether 
ubiquitination promotes CREBH stability and subsequent translocation to the nucleus. To 
address that question, we transiently overexpressed CREBH, TRAF6, and different 
ubiquitination mutants in Huh7 cells. Western blot analysis with cellular protein fractionations 
showed that expression of K63O led to the highest levels of translocation of CREBH into the 
nucleus, compared to expression of the other ubiquitin isoforms (Fig 14A). However, 
expression of K48O led to more CREBH localized to the ER and cytosolic fractions than that 
localized to nucleus (Fig 14A). When K63R mutant was expressed, the trend reversed, as more 
CREBH protein was present in the nuclear fraction. Additionally, expression of K33O also led 
to more CREBH protein was present in the nuclear fraction (Fig 14A). Although the role of 
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K33-linked ubiquitination in protein stability is not well defined, it is possible that K33-linked 
ubiquitination, like K63-linked ubiquitination, can stabilize protein, an interesting question to 
be elucidated in the future. Taken together, my studies indicated that K63-linked ubiquitination 
of CREBH, mediated through TRAF6, can stabilize CREBH protein and facilitate the 
translocation of cleaved CREBH into the nucleus, a part of CREBH activation process. 
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Figure 14. LPS treatment enhance the stability of CREBH protein at early time points after
cycloheximide treatment. 
(A) Effect of LPS on CREBH protein stability. Protein stability of CREBH was determined 
by the protein half-life examination after cycloheximide (100μM) was added. Top right 
panel: Huh7 cells infected with Flag-tagged CREBH adenovirus after 72hr treatment with 
LPS for 4hr, cycloheximide was added and the CREBH protein levels were assessed by 
Western blot analysis. Huh7 cells were incubated with cycloheximide for the indicated times 
periods and the cell lysates was harvested for Western blot analysis. Densitometry analysis of 
CREBH precursor protein (B) and cleaved CREBH protein (C) with β-actin as loading 
controls. Densitometry analysis was done with ImageJ software. 
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Figure 15. K63-linked ubiquitination enhances nuclear localization of CREBH  
Western blot analysis of enrichment of CREBH in nuclear and cytosolic/ER fractions isolated 
from HEK293T cells transfected with Flag-tagged human full-length CREBH along with 
different ubiquitin mutant plasmids as indicated in panel (A) and with mutant TRAF6 and 
mutant Ub (B).  CREBH, GAPDH (cytosolic marker), and Lamin B1 (nuclear marker) protein
signals were detected by Western blot analysis using the polyclonal anti-CREBH, anti GAPDH, 
and anti-Lamin-B1 antibody. 
 
61 
 
 
CREBH cleavage and activation involves the PI3K-AKT-GSK3 axis pathway. 
 
LPS treatment in macrophages triggers activation of PI3K-AKT signaling pathway 
(114). To test whether the PI3K-Akt-GSK3 regulatory axis is involved in CREBH activation,  
we isolated primary hepatocytes from wild-type mice and pretreated them with PI3K inhibitor 
LYS294002 (50μM/ml, 1hr before treatment) and LiCl (30mM/ml,2hr pretreatment). After the 
pre-treatment, the primary hepatocytes were treated with LPS (100ng/ml) for 4hr. Western blot 
analysis showed that the pre-treatment with PI3K inhibitor reduced the levels of cleaved 
CREBH protein, compared to the vehicle pre-treatment, in response to LPS challenge (Fig 
16A). Notably, the pre-treatment with LiCl, the GSK3 inhibitor increased the levels of cleaved 
CREBH (Fig 16A). These results suggest that the PI3K-Akt-GSK3 regulatory axis may be 
involved in CREBH cleavage and activation. 
PI3K and GSK3 are all connected to the Akt-mediated signaling pathway. Our previous 
study showed that insulin signal can activate CREBH in the liver and primary hepatocytes (72). 
Together with my study with PI3K and PP2A inhibitors, all these results suggest that Akt 
pathway may be an upstream regulator of CREBH activation. To further validate this 
hypothesis, I over-expressed wild-type and dominant negative Akt in Huh7 cells. While 
overexpression of wild-type Akt elevated the levels of cleaved CREBH, expression of the 
dominant negative Akt reduced the levels of cleaved CREBH in Huh7 cells (Fig 16B). This 
result confirmed the role of Akt in CREBH cleavage and activation.  
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Figure 16. PI3K- Akt-GSK3 axis pathway is involved in CREBH cleavage and activation. 
(A)Primary hepatocytes isolated from wild-type mice were treated with LPS (100ng/ml) for 
4 hr. along with pretreatment with Lys294 for 30 min and LiCl for 2hr. Western blot analysis 
was performed to detect endogenous CREBH cleavage using a polyclonal anti-CREBH 
antibody with Actin as loading control. (B) Western Blot analysis showing CREBH cleavage 
in Huh7 cells co-transfected with full length human CREBH and Wild type Akt or dominant 
negative Akt. 
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Discussion 
 
In this chapter, I showed that the interact to induce ubiquitination of CREBH under 
inflammatory stress. This confirmed the role of the E3 ligase activity of TRAF6 in CREBH 
activation under TLR4 signaling stimulation.  K63-linked polyubiquitination is associated with 
programing the molecules for downstream signaling (115). This is the first demonstration that 
CREBH undergoes K63 ubiquitination upon TRAF6 interaction. The ubiquitination is due to 
the E3 ligase activity of TRAF6 since TRAF6 C70A mutant failed to show ubiquitination of 
CREBH protein. Expression of the K63O mutant led to CREBH cleavage comparable to wild-
type Ub. In my study, K33- and K63-linked ubiquitination had similar effects on CREBH 
cleavage. This ubiquitination appears to be necessary to increase the stability of the CREBH 
precursor proteins since LPS treatment increases the protein half-life. A soluble factors 
ESCRTO protects the K63-ubiquitinated proteins from proteasomal degradation (116). We 
concluded that  ubiquitination of CREBH primes it for subsequent CREBH cleavage and 
activation process. My study also revealed the involvement of another PTM, Akt-mediated 
phosphorylation, in CREBH cleavage. This modification may be correlated with TRAF6-
mediated ubiquitination process since TRAF6-mediated ubiquitination can enhance 
phosphorylation and membrane recruitment of Akt (107). 
Ubiquitination of CREBH likely facilitates its nuclear transport, although the exact role 
of ubiquitination in CREBH cleavage and activation needs to be investigated further. My 
findings suggest that K63-linked ubiquitination of CREBH is a critical event that regulates 
CREBH cleavage in response to TLR4 activation. However, I also detected low levels of 
CREBH ubiquitination that may be due to basal homoeostatic activity of CREBH. 
Additionally, Akt-mediated phosphorylation of CREBH appeared to be important to CREBH 
cleavage. However, Akt may not directly target on CREBH for its phosphorylation. Instead, 
Akt may be involved in cargo assembly and vesicular transport for CREBH, as transport and 
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activation of SREBP1c, an ER-anchored transcriptional factor similar to CREBH, are mediated 
through COPII vesicles that involve Akt-mediated phosphorylation through Akt (117). The 
similar mechanism involving Akt-mediated phosphorylation might exist in the case of CREBH 
translocation from ER to Golgi under the endotoxin challenge. In short, in this chapter, I 
demonstrated that the posttranslational modifications, namely ubiquitination and 
phosphorylation, are critical for CREBH activation under LPS treatment. I also provided a 
detailed molecular mechanism for TRAF6-mediated ubiquitination of CREBH and its role in 
CREBH cleavage and activation.  
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CHAPTER 4: DETERMINING THE CREBH TARGETS 
UNDER INFLAMMATORY STRESS 
 
 
Summary  
In this chapter, I evaluated the transcriptional targets of CREBH. Specifically, I 
determined inflammatory stress-specific genes targeted by CREBH. CREBH, as a liver-
specific transcription factor, has already been shown to be involved in transcription of acute 
phase response proteins, such as cis-reactive protein (CRP) and serum amyloid component P 
(SAP). Previously, Zhang et al proved that CRBEH is a master regulator of hepatic lipid 
metabolism (87).  Additionally, research in our lab showed that CREBH regulates transcription 
of genes associated with lipid metabolism. Microarray and qRT-PCR studies by Zhang et al 
have shown that deletion of CrebH in the liver decreased the expression of five groups of genes 
encoding functions critical for lipid metabolism 
Phenotypically, deletion of CREBH increases serum TG levels and hepatic TG contents 
(118). In a bacterial sepsis model, CREBH mRNA levels were reduced due to bacterial 
sepsis.Protective treatment with melatonin, seems to restore and elevate the expression of 
CrebH mRNA (119). Hepatitis B virus (HBV) seems to exert its oncogenic effect through 
CREBH. One of the protein Hepatitis B virus protein X (HBx) showed to interact with CREBH 
to induce activation of critical transcription factors like c-Jun and AP1 (120). CREBH is shown 
to be synergistically involved in the oncogenic effect of HBV.  The interaction between 
CREBH and HBx is necessary for proliferation of Hepatocellular carcinoma cells and mouse 
primary hepatocytes. Additionally, Varicella zoster virus infection also modulates CREBH 
expression for its successful infection in host cells. In a microarray study, VZV infection 
upregulates CREBH expression by 64-fold, compare to mock-infected cells. Besides, VZV 
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mediated up-regulation is more than the up-regulation induced by ER stress inducer 
tunicamycin (121). 
CREBH is linked to many upstream receptors for its pathophysiological effect through 
stress-induced CREBH cleavage and CREBH transcriptional activation of target genes. HCV 
exerts its effect on glucose metabolism through the endocannaboid receptor 1. Treatment with 
endocanaboid receptor agonist upregulates CREBH expression which in turn cause up-
regulation of PEPCK and G6Pase expression levels (122). In this chapter, I evaluated the 
inflammatory stress-induced transcriptional regulation through CREBH. I identified the 
specific gene targets of CREBH under LPS treatment and the capacity CREBH in regulating 
transcription of these genes.  
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Material and Methods 
 
Quantitative real-time PCR 
For real-time PCR analysis,  reaction mixtures containing cDNA template, primers and 
SYBR Green PCR Master Mix (Applied Bio systems)were analyd   with 7500 Fast Real-time 
PCR System (Applied Bio systems, Carlsbad, CA). Fold changes of mRNA levels were 
determined after normalization to internal control Rplpo or β-actin mRNA Levels.  The 
sequences of real-time PCR primers used in this study are shown in Appendix B 
 
Luciferase reporter analysis 
For luciferase reporter analysis, we used the Dual-Luciferase Reporter Assay System 
(Promega Inc).  Huh7 cells were co-transfected with the reporter vectors and control reporter 
vector, and the vector expressing full-length CREBH.  Luciferase assay was performed at 24, 
36, 48 hr after transfection/infection. Data graphs were presented as normalization of Firefly, 
luciferase reporter activities to the control Renille luciferase activities.  
 
Chromatin immunoprecipitation (ChIP) Assay 
 
Mouse liver tissues from LPS injected animals were isolated, homogenized in 10ml 
Wheaton tissue grinder, and suspended in  NP-40 lysis buffer  (HEPES 20mM,ND40 0.5%, 
NaCl 10mM, MgCl2 3mM, Na4P2O7 10mM, NaF 1mM, sodium butyrate 10mM, sodium 
vanadate 10mM, DTT 1mM, spermidine 0.5mM, spermine 0.15mM). The nuclear pellets were 
isolated using two-step gradients of 1M and 0.5M sucrose. The morphological integrity 
of isolated nuclear fractions was assessed with DAPI staining. For the crosslinking procedure, 
formaldehyde was added directly to the pellet and the reaction was stopped with 200mM Tris-
HCL. Purified nuclear fractions were first sonicated 10 times for 10s and then subjected to 
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immunoprecipitation with the anti-CREBH antibody-coated recombinant protein G beads 
(Invitrogen, Grand Island, NE, USA). The amount of chromatin used was 3μg/μg antibody.  
Eluted DNA was subjected to quantitative RT-PCR as well as semi-quantitative PCR analysis.  
 
Quantitative Real-time PCR for ChIP 
Real-time PCR was carried out with SYBR-Green-based reagents (Invitrogen, express 
SYBR Green ER) using immunoprecipitated DNA-protein complex on an Applied Biosystems 
7500 Fast protocol. The relative quantities of immunoprecipitated DNA fragments were 
calculated using the comparative CT method. Resulting quantitation was determined after 
normalizing to antibody control. Results were compared to a standard curve generated by serial 
dilutions of input DNA. Data were derived from three independent amplifications. Error bars 
represent standard error of the mean. 
 
Statistics 
Experimental results are shown as mean ± SEM (for variation between animals or 
experiments).   All in vitro experiments  were repeated with biological triplicates at least three 
times independently. Mean values for biochemical data from the experimental groups were 
compared by paired or unpaired, 2-tailed Student’s t-tests. Multiple comparisons were 
compared with ANOVA and proceeded to ad hoc statistical test when necessary.  Statistical   
tests with P < 0.05 were considered significant. 
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Results 
 
CREBH regulates transcription of the genes involved in TG metabolism under the 
endotoxin challenge.  
Previously, we demonstrated that Crebh null mice displayed elevated levels of serum 
and hepatic TG under the atherogenic high-fat diet (72). To understand the genetic basis 
underlying the lipid phenotypes observed with the CrebH null mice, we performed quantitative 
real-time PCR (qRT-PCR)  with total liver mRNA from the CrebH null and wild-type control 
mice fed on normal chow but injected with either vehicle PBS or LPS. Through the qRT-PCR 
analysis, we have identified a group of lipid metabolism-associated genes were upregulated by 
LPS treatment (Fig 17A and 17B). Most of the metabolic genes, such as ApoA-IV, ApoA5, 
ApoC2, and ApoB, we investigated showed changes in expression upon LPS treatment. 
However, expression levels of these genes, except ApoA-IV, were only marginally affected by 
CREBH deletion. In case of Apo A-IV, the mRNA levels under CrebH null condition were 
significantly lower, compared to the wild-type mice (Fig 18A). At the protein level, hepatic 
Apo A-IV levels were elevated in wild type mice injected with LPS. In contrast, levels of Apo 
A-IV in the livers of CrebH null mice were lower than that of wild-type control mice (Fig 18B). 
Moreover, the levels of serum ApoA-IV in the CrebH null mice were significantly lower than 
those in the wild-type control mice (Fig 18C). 
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CREBH regulates expression of the genes involved in the pro-inflammatory response to 
endotoxin challenge. 
            Previously, the CREBH transcription factor has been shown to be associated with 
transcription of the genes encoding acute phase response proteins and hepcidin, a gene 
associated with iron metabolism (123). Bearing this in mind, I investigated the role of CREBH 
in regulating expression of the genes involved in acute inflammation under the LPS challenge. 
qRT-PCR analysis with the total RNA from the CrebH null and wild-type control mouse livers 
showed that levels of IL-6 mRNA were significantly decreased in the liver of CrebH null mice, 
compared to that of the control mice, upon LPS challenge (Fig 17C). Moreover, expression of 
the genes encoding the chemokines CCL2 and RANTES were also decreased in the CrebH null 
mice in the presence or absence of LPS challenge (Fig 17C). 
            In the liver, IL-6 mRNA levels can be contributed by different liver cell populations, 
such as Kupffer cells, hepatocytes, and hepatic stellate cells. We tested whether CREBH, a 
hepatocyte-specific transcription factor, directly regulates IL-6 transcription in hepatocytes. In 
order to answer this key question, we evaluated IL-6 mRNA levels in the primary hepatocytes 
isolated from CrebH null and wild-type mice in response to LPS challenge.  As shown in (Fig 
19B), IL-6 mRNA levels were abrogated in CrebH null mice (Fig 19B). This observation is 
consistent with our analysis with whole liver mRNA. Hence, our data suggested that CREBH 
transcription factor has a major role in transcription of IL-6 gene in the liver hepatocytes under 
LPS treatment. 
 
 
 
71 
 
 
 
 
  
Figure 17. CREBH transcription profile under LPS treatment. 
Total RNAs were isolated from liver tissues of the CrebH null and wild-type control mice under 
the normal chow diet after LPS (2μg/gm body weight) injection  and subjected to quantitative 
real-time RT-PCR analysis of expression of the genes involved in apolipoproteins (A), lipid and 
glucose metabolism (B), and inflammation (C). Expression values were normalized to Rplpo or 
β-actin mRNA levels. Fold changes of mRNA levels are shown by comparing to one of the 
control mouse under the normal chow diet. Each bar denotes the mean ± SEM (n=3). * P<0.05; 
** P<0.01 
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Figure 18. LPS injection increases hepatic Apo A-IV levels in liver but not in serum. 
(A) mRNA levels of Apo A-IV gene transcription from primary hepatocytes isolated 
from wild type and CrebH null mice under the normal chow diet treated with LPS 
(100ng//ml).Western blot analysis of wild type and CrebH null mice injected with LPS 
(2μg/gm body weight) for 18hr displaying Apo A-IV protein levels in liver (B) and in 
serum (C) Each bar denotes the mean ± SEM (n=3). * P<0.05; ** P<0.01 
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CREBH binds to the Apo A-IV and IL-6 gene promoters and is involved in transcription 
of these genes. 
To determine whether the transcriptional down-regulation observed for IL-6 and Apo 
A-IV in our qRT PCR studies were direct effects of CREBH binding, we performed ChIP 
experiments to test the potential of CREBH in binding to the promoter regions of the IL-6 and 
Apo A-IV genes. We performed endogenous ChIP analysis on whole liver tissues challenged 
with LPS. The ChIP analysis indicated that CREBH can bind to the promoter regions of the 
genes encoding Apo A-IV (Fig 19A and B). Further, we confirm that under Myd88 null 
condition binding of CREBH was diminished with LPS treatment, thus further confirming that 
TLR4-mediated CREBH activation is necessary for Apo A-IV transcriptional activation (Fig 
19D and 19E). Similarly, treatment with LPS leads to elevated binding of CREBH to the IL-6 
promoter region (Fig 20E) 
Next, we confirmed the transcriptional role of CREBH in gene transcription of Apo A-
IV and IL-6 by gene expression reporter assays Huh7 cells were co-transfected with the vector 
expressing full-length CREBH and the vector expressing Apo A-IV or IL-6 luciferase reporter.  
Expression of CREBH increased transcription of Apo A-IV genes, as indicated by high levels 
of luciferase activity driven by the Apo A-IV gene promoter (Fig 19C). This increase was almost 
8-10 folds, compared to reporter control. Further, I determined the effects of CREBH 
transcription activity on Apo A-IV gene promoter at different time points ranging from 24, 36 
to 48hr. Apparently, CREBH exerted its strongest transcriptional activity in driving the Apo A-
IV promoter at 36 hr post the plasmid transfection (Fig 19C). 
In case of IL-6 reporter assay, we observed the considerable basal level of IL-6 gene 
transcription without CREBH overexpression (Fig 20C-D). The basal level of IL-6 reporter 
activity may be due to the contribution of endogenous NF-κB transcription activity triggered 
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by plasmid transfection and expression. Consistently, overexpression of CREBH and IL-6 
reporter displayed 1.5-2 fold increase in IL6 reporter activity over the endogenous IL-6 reporter 
activity. In order to determine the exact effect of CREBH on IL-6 transcription without any 
contribution from NF-κB, I used IL-6 reporter defective for NF-κB transcription factor binding 
site (Fig 20C). Under NF-κB defective IL-6 reporter overexpression, CREBH overexpression 
displayed a higher level of activity in increasing IL6 reporter activity (Fig 20C-D). This result 
confirmed the direct role of CREBH transcription factor in the IL-6 promoter. Additionally, I 
also tested whether CREBH interacts with NF-kB transcription factor for IL-6 transcription. I 
observed that co-expression of CREBH and P65 subunit of NF-κB led to a reduction in IL-6 
reporter activity, compared to P65 subunit alone (Fig 20C), suggesting that CREBH may 
compete NF-κB in activating IL6 promoter, an interesting question to be evaluated in the 
future.  
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Figure 18. CREBH binds to Apo A-IV promoter under LPS treatment and this 
binding is TLR4 signaling dependent. 
 ChIP analysis of CREBH-binding activity to the promoter regions of the Apo A-
IV. Chromatin isolated from the wild type mouse liver were subjected to 
immuoprecipitation. PCR was performed to identify potential CREBH-binding 
regions in the Apo A-IV promoter. Mock ChIP with control antibody was included 
as a control (HA). The PCR reactions with the genomic DNA isolated from 
sonicated cell lysates were included as positive controls. (A) Semi-quantitative 
ChIP analysis of wild type mouse injected with LPS (2μg/gm body weight) (B) 
quantitative PCR analysis of LPS injected liver tissue C) Luciferase activity of 
CREBH at Apo A-IV gene promoter in Huh7 cells infected with full length human 
CREBH plasmid along with Apo A-IV reporter. (D) ChiP analysis showing 
CREBH binding to Apo A-IV in wild type and Myd88 null mice. (E) Semi-
quantitative analysis of wild type and Myd88 null liver samples. Each bar denotes 
the mean ± SEM (n=3). * P<0.05; ** P<0.01 
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Discussion 
 
 
Figure 19.  CREBH binds to IL-6 promoter under LPS treatment and this binding is 
TLR4 signaling dependent. 
Levels of IL-6 in wild type and CREBH null mice injected with LPS (2μg/gm body weight) in 
serum (A) and mRNA levels of IL-6 in primary hepatocytes(B). ChIP analysis of CREBH-binding 
activity to the promoter regions of the Apo A4. Luciferase activity of CREBH transcription factor 
at IL-6 promoter (D) transcriptional activity of CREBH at IL-6 promoter along with NF-κB 
transcription factor. (C). (E) ChIP analysis of CREBH binding activity to the promoter region of 
IL-6. Chromatin isolated from the wild type mouse liver were subjected to immuoprecipitation . 
PCR was performed to identify potential CREBH-binding regions in the IL-6 gene promoter. Mock 
ChIP with control antibody was included as a negative control (HA). The PCR reactions with the 
genomic DNA isolated from sonicated cell lysates were included as positive controls. Each bar 
denotes the mean ± SEM (n=3). * P<0.05; ** P<0.01 
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Discussion 
 
As a liver-specific transcription factor, CREBH regulates an array of genes associated 
with TG and lipoprotein metabolism (72). The impact of CREBH on apolipoprotein had been 
proved previously (124). To further exploit the regulatory impact of CREBH on apolipoprotein 
metabolism, we have investigated the mechanism through which endotoxins and innate 
immunity regulate Apo A-IV biosynthesis. Hepatic levels of Apo A-IV elevated upon LPS 
injection, and it was abrogated with the loss of CREBH from mouse liver. It has been suggested 
that there are two cis-acting elements on the Apo A-IV promoter bound by CREBH transcription 
factor that controls the transcription of Apo A-IV (124).  Previously it had been described that 
Apo A-IV and Apo A-V are acute phase proteins in mouse HDL (125). The increase in 
apolipoproteins level to inflammation is a well-documented response to inflammatory stimuli. 
There is a prevailing theory that immune cell produced IL-6 can stimulate hepatocytes 
to produce acute phase response proteins. CREBH in hepatocytes was previously reported to 
be involved in acute phase response gene transcriptions (87). Production and secretion of IL-6 
are paramount in injuries. Any damage will elicit immune reaction resulting in IL-6 secretion 
in circulation, which eventually reach the liver and trigger an acute phase response. In case of 
liver injuries, it is thought that the endogenous immune cells in the liver are responsible for IL-
6 production (126). It has been demonstrated that hepatocytes play an important role in IL-6 
production since selective inactivation of NF-κB in hepatocytes caused abrogated production 
of IL-6 (127). Our study has shown for the first time that CREBH transcription factor is 
involved in IL-6 production from hepatocytes. Bioinformatics data points at two potential 
CREBH binding sites at IL-6 gene promoter, exact location of these sites are yet to be 
confirmed  Surprisingly potential binding sites of CREBH overlaps with another transcription 
factor binding site CEBP/β. CEBP/β has been shown to be involved in inflammatory gene 
transcription along with NF-κB. This finding perhaps explains the decrease in IL-6 reporter 
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activity when CREBH co-transfected with the P65 subunit of NF-κB, since NF-κB, factor 
requires CEBP/β for its transcription activity of IL-6. This mechanism can be a potential way 
to control the excessive inflammatory response to incoming endotoxins in the liver. My 
reporter assay with CREBH and IL6 promoter revealed some of the interesting facts about the 
regulation of inflammation by hepatocytes. Since hepatocytes are the first responder in liver 
against exposure to antigens from portal blood flow, they need to maintain low levels of 
inflammatory activity in order maintain the tolerance to those antigens. My study suggested 
that CREBH is involved in basal or low levels of inflammatory activity. Exposure to high levels 
of endotoxins or inflammatory stimuli may lead to CREBH competition with classical 
inflammatory transcription factors like NF-κB, CEBP/β, and AP1, an intriguing question to be 
elucidated in the future.  
Another important observation from my experiments is the differential behavior of 
CREBH on activating its target genes. My study unveiled how CREBH transcription activity 
was modulated based on the types of stress. Under endotoxin-mediated CREBH activation, 
unlike its previously enlisted genes under the atherogenic high-fat diet (AHF), CREBH 
selectively activates transcription of Apo A-IV and IL-6. Notably, under the metabolic stress, 
activation of CREBH has no effect on driving expression of IL-6 (data not shown). My study 
suggested that CREBH has an ability to respond to various stress and control an array of gene 
expression as per the stress requirement. 
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CHAPTER 5: Delineating the animal phenotypes caused by 
CREBH deletion 
 
Summary  
 
IL-6 is considered as pro-inflammatory cytokine and one of the immediate responders 
to inflammation. Recent studies suggested that IL-6 might be involved in dampening the 
immune response through suppressing the production of TNFα and IL-1β (128). A population 
study of obese and insulin resistant individuals pointed at the correlation between increase 
serum levels of IL-6, obesity, and insulin resistance (129). Common polymorphism associated 
with IL-6 includes SNP in the IL-6 gene 174G to C substitution, has been independently 
associated with type-2 diabetes (130). IL-6 not only affects insulin signaling but also exerts its 
effect through manipulating the lipid metabolism in the body. IL-6 transgenic mice have low 
total cholesterol and TG levels (131). Treatment of Hep3B cells with recombinant IL-6 for 
24hr increased levels of the nuclear receptor PPARα while decreased levels of SREBP-1c. IL-
6 can increase the FA oxidation in rat muscles (132), and is targeted on hepatocytes to modulate 
apolipoprotein levels (133).  
Apo A-IV, as discussed in previous chapter, is a component of chylomicrons and HDL. 
The level of Apo A-IV can serve as a surrogate marker of lipid absorption and secretion (134). 
Approximately 25% of Apo A-IV is attached to HDL particles while the rest of is found as a 
free fraction of plasma. Apo A-IV synthesis can be triggered by glucocorticoids as well as 
insulin (135). Functions of Apo A-IV include: 1) activating lecithin: cholesterol 
acyltransferase, 2) modulating the activities lipoprotein lipase, and 3) cholesterol ester transfer 
protein, and 4) facilitating cholesterol removal from peripheral cells. 
Interestingly, recent studies suggested that Apo A-IV inhibits gastric emptying and 
serves as a satiety factor in response to ingestion of dietary fat (136), Two mutations in Apo 
A-IV protein, including Gln360 His and Thr347 Ser associated with lipid and lipoprotein 
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metabolism (137). Given the evidence that Apo A-IV may be involved in the inhibition of food 
intake following consumption of a high-fat meal, we examined the potential effects of these 
Apo A-IV defects on indices of body weight and food consumption.  
Previously, we demonstrated that CrebH null mice displayed reduced body weights, 
increase hepatic steatosis, reduction in abdominal fat, and hypertriglyceridemia under the 
atherogenic high-fat diet (137). Since in the previous chapter I described the roles of CREBH 
in transcriptional regulation of Apo A-IV and IL-6, here I explored the impact of CREBH 
deficiency in hepatic and serum TG, serum cholesterol, and energy consumption under the LPS 
challenge. 
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Material and Methods 
 
Measurement of mouse lipid metabolites 
Liver tissue and blood plasma samples were isolated from the mice under  normal chow 
diet after LPS (2μg/gm body weight) challenge for 18hr. To determine hepatic TG levels, 
approximately 100 mg  liver  tissue was  homogenized  in 500 μl PBS followed by 
centrifugation at 10000g for 5 min. The supernatant was mixed with 500 μl 10% Triton-100 in 
PBS for TG measurement using a commercial kit (Bioassay Systems,CA). Mouse hepatic TG 
levels were determined by normalization of liver tissue mass used for TG measurement.  Mouse   
blood plasma   samples were subjected to quantitative   analyses   of   TG using a commercial 
kit (Bioassay Systems, CA). 
 
Indirect calorimetry 
Each mouse was monitored individually in the computer-controlled OxyScan open 
circuit indirect calorimetry system (AccuScan Instruments, Columbus, OH) (Bishop and 
Walker 2004) with free access to food and water. Oxygen consumption (VO2) and carbon 
dioxide production (VCO2) were measured for 18 hr after PBS or LPS (2mg/kg body weight) 
challenge. Gas analyzers were calibrated to room air drawn through each chamber at a rate of 
0.5 L/minute. 
 
Steady-state measurements of plasma glucose after LPS injection 
Basal plasma glucose levels were measured at the termination of the experiment. 
Blood was sampled from the tail tip using a cut below the vertebrae. Glucose was measured 
by a hand-held glucose meter (One-Touch Ultra; Johnson and Johnson). 
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Body weight measurement and food consumption 
Wild-type and CrebH null mice were subjected to food intake measurement under the 
normal chow diet before LPS injection and 18hr after injection. Body weights were measured 
similarly before and after LPS injection. 
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Results 
 
Under LPS challenge, absence of CREBH causes elevation in serum TG levels. 
Since CREBH have been shown to be involved in manipulating levels of Apo A-IV, I 
tested the effect of CREBH on modulation Apo A-IV under LPS challenge. In order to reveal 
the pathophysiological effect of CREBH on TG levels, we measured hepatic, and serum TG 
levels in LPS-injected mice (Fig 22A). We found a comparable increase in TG levels post LPS 
injections in wild-type and CrebH null mice. We thus inferred that TLR4-CREBH- Apo A-IV 
axis pathway does not affect hepatic TG levels. Interestingly, CrebH null mice displayed 
elevated basal levels of serum TG, which were increased further after LPS injection (Fig 22B).   
 
CREBH plays an important role in endotoxin-mediated cholesterol modification. 
Apo A-IV is a component of chylomicrons as well as HDL cholesterols (138, 139). 
Transportation of TG from the intestine to tissues takes place through chylomicrons. Hence 
chylomicron, being an intestinal cargo transport, cannot be a good indicator for the function of 
CREBH- Apo A-IV regulatory axis. In order to reveal the impact of abrogated production of 
Apo A-IV in the absence of CREBH, we tested the serum cholesterol levels of CrebH null mice 
after LPS challenge. We observed that CrebH null mice had a slight increase in total 
cholesterol, HDL, and LDL upon LPS treatment (Fig 22C), while wild-type mice treated with 
LPS displayed a significant increase in total cholesterol and HDL levels, compared to control 
mice treated with vehicle (Fig 22D). CrebH null mice did not display such elevation upon LPS 
treatment. HDL levels of LPS-injected CrebH null mice were significantly lower than those of 
LPS-injected wild type mice. There was no significant difference in LDL/VLDL levels 
between CrebH null and their corresponding control mice (Fig 22E). 
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Figure 20. LPS mediated HDL cholesterol changes are dependent on TLR4-CREBH 
axis pathway. 
Serum and hepatic lipid profiles of mice challenged with LPS (2μg/gm body weight) for 
18hr (A) Serum TG levels in LPS injected mice (B) Hepatic TG levels in LPS injected 
mice. Serum levels of (C) Total cholesterol (D) HDL (E) LDL/VLDL in LPS injected 
mice. Each bar denotes the mean ± SEM (n=5). * P<0.05; ** P<0.01 
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LPS-challenged CrebH null mice displayed increased oxygen consumption and reduced 
blood glucose levels. 
Since we have observed a change in lipid and cholesterol profile of CrebH null mice 
after LPS challenge, we investigated the physiological processes that may contribute towards 
this phenotype. LPS injected mice displayed loss of body weight post LPS injection while PBS 
injected mice did not lose significant body weight post-treatment (Fig 23C). Even the food 
consumption is consistent with the body weight loss; LPS injected mice consumed less food 
while the PBS injected mice consumed about 2-3 gm more food over 18hr (Fig 23B). 
We also investigated the energy expenditure through indirect colorimetric analysis. The 
oxygen consumption for LPS-injected mice displayed lower energy expenditure compared to 
the PBS-injected mice (Fig 20A). The decrease in oxygen consumption levels in LPS injected 
mice is in part due to the inflammation induced caused by LPS action. Compared to the wild-
type animals, CrebH null mice exhibited relatively higher oxygen consumption. This may 
reflect a feedback regulation of impaired lipid profile in the CrebH null mice. Additionally, we 
measured plasma glucose levels of CrebH null and wild-type control mice upon LPS challenge. 
LPS injected mice CrebH null mice displayed low levels of blood glucose compared to wild-
type mice (Fig 23D).  
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Figure 21. LPS mediated physiological changes are comparable in wild type and CREBH 
null mice. 
Physiological parameter analysis in LPS (2μg/gm body weight) for 18hr injected mice (A) 
Energy expenditure in wild type and CREBU null mice displayed with VO2 levels. Food 
consumption (B) Body weights (C), Blood glucose levels (D) of CrebH null and wild-type 
control mice under the normal chow diet after LPS injection (2μg/gm body weight).  
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Discussion 
 
Lipid metabolism abnormalities are a critical issue in all sepsis patients. Plasma proteins 
like apolipoproteins are markedly modulated during sepsis. HDL is thought to play a protective 
role in sepsis and endotoxemia (140). Elevation in HDL levels is an important response 
mounted by the body to counter the sepsis or endotoxin levels. Elevation in HDL post LPS 
injections confirms the previous findings. Our study in this chapter reveals one of the 
underlying mechanisms explaining the role of the hepatic transcription factor CREBH in a 
protective response to endotoxins. TLR4 mediated activation of CREBH that in turn increases 
transcription of Apo A-IV, a component of HDL cholesterol, is a critical signaling pathway for 
against sepsis. Our study indicates that the loss of CREBH damaged the ability of the animal 
to mount an HDL protective response against LPS. Previously, the release of TNFα increase 
levels of TG and cholesterol in LPS injected mice (141). It had been shown CrebH null mice 
had lower levels of serum cholesterol and TG (72). The increase in TG and cholesterol after 
LPS injection is a well-documented effect known to carry through an unknown mechanism. 
Our study with CrebH null mice have shed light on the possible mechanism of elevation in 
serum TG levels post LPS treatment. The activities of inflammatory cytokines have been 
suggested to be the main cause in inhibiting energy accumulation. Inflammation induces energy 
expenditure and inhibits food intake. Study with the transgenic mouse has confirmed this 
notion (142). Injection of IL-10 shown to reduce the LPS-mediated changes in body weight 
and food consumption (142). Injection of LPS decreases not only glucose production but also 
glucose utilization. Studies showing that acute exposure to LPS inhibits glucose production, 
conflicting reports about the effect of LPS on glucose uptake (143, 144). We found a possible 
mechanism of elevation in HDL cholesterol after endotoxin treatment, which is mediated 
through CREBH in a TLR4-dependent manner. Our study with CrebH null mice showed that 
the null mice have elevated levels of serum TG after endotoxin treatment, which is consistent 
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with a previous study that CrebH null mice being more prone to steatosis under HFD (72). 
Therefore, high-fat diet may induce steatosis by increasing serum and hepatic TG through 
CREBH (145). Additionally, investigation of energy expenditure, food consumption, and body 
weights have revealed the inflammation-related effect on mouse energy metabolism. Study 
with physiological parameters mentioned above help us to confirm the effect of the TLR4-
CREBH-Apo A-IV regulatory axis on cholesterol and TG metabolism. 
Work in this chapter shows the effect of endotoxin on lipid metabolism through 
activation of CREBH. This effect, in presence of low endotoxin levels, could be an important 
response to bacterial infection.  
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CHAPTER 6: Conclusions and Significance 
 
In this study, we conclude that CREBH plays a critical role in connecting innate 
immunity with metabolic signaling during acute endotoxin challenge. This  conclusion is based 
on the following findings: (1) The endotoxin LPS is capable of inducing expression and 
cleavage of CREBH; (2) TRAF6; the E3 ligase under the TLR4 signaling pathway, is capable 
of interacting with full-length CREBH at ER membrane in hepatocytes; (3) CREBH activation 
requires posttranslational modification by TRAF6-medaited ubiquitination; (4) CREBH does 
not contribute to the transcroption of classical UPR or metabolic genes described previously 
but it is required for the APR associated genes by regulating transcription of the ApoA 
IV  and IL-6 genes; (5) CREBH binds to a promoter element in the ApoA IV  and IL-6  gene 
sequence; (6). CREBH upon binding to ApoA IV promoter regulates the levels of HDL and 
triglycerides. Our study sheds light on the intriguing mechanism behind the connection 
between immune signaling and hepatic metabolism in acute endotoxemia. We demonstrate that 
host response against the infection involves a highly sophisticated cross communication 
between innate immune signaling and transcription factor associated with hepatic metabolism. 
Our study confirms the widespread notion that immune signaling has a pronounced effect not 
only on innate immunity but also modulation of hepatic metabolism. Changes in metabolism 
are integral parts of the immune response against endotoxins, even bacterial infections. 
  Our studies also provide insight into the role of the posttranslational 
modification, namely ubiquitination, in CREBH cleavage and activation mechanism.The 
ability of the same protein to function differentially in response to the wide range of cues is 
attributed to post-translational modifications (146). It is known that TRAF6, an E3 ligase in 
the TLR4 signaling pathway, is involved in regulation and activation of downstream target 
molecules through ubiquitination (147). Our study expanded and confirmed the role of TRAF6 
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from being involved in inflammatory responses to be an essential player of metabolic 
signaling. The role of bacterial infection in metabolic disorders, such as atherosclerosis, is well 
studied. Inflammation is known to contribute significantly to the atherosclerotic process and is 
associated with proatherogenic changes in lipoprotein metabolism that was characterized by 
increased VLDL and reduced HDL levels (39).  Males with lower levels of HDL are more 
susceptible to inflammatory stimuli against endotoxin challenge (148). Considering the 
protective role of HDL, administration of recombinant high-density lipoprotein (rHDL) to 
prevent bacterial infection-associated pathogenesis inflammatory effects (149). Indeed, rHDL 
showed increased capacity of anti-inflammatory and anti-oxidant functions in the approaches 
related to prevention and treatment of atherosclerosis (150). 
The CREBH knockout mouse model provided a tool to validate the functional impact 
of LPS-induced, TLR4-mediated CREBH activation in the liver. CrebH null mice had 
abrogated levels of serum HDL, compare to their wild-type controls, upon relatively low-dose 
of LPS challenge. Our studies using the CrebH null mouse revealed that TLR4 mediated 
signaling is required to induce the acute phase response. Further studies to evaluate the 
response to a high dose of endotoxins or breakdown of TLR4-CREBH signaling axis under 
sepsis condition need to be pursued in the future. Alternatively, as we previously showed, 
CrebH null mice displayed hepatic steatosis and hyperlipidemia under the atherogenic high-fat 
(AHF) diet (72). Interestingly, CrebH null mice under the AHF diet produced low levels of 
serum HDL. This observation implied that the metabolic diet may also activate the same 
pathway mediated through TLRs, an intriguing question to be answered in the future.    
  Our studies at the intersection of immunity and metabolism leave out a lot of open 
questions. Although we can delineate the role of ubiquitination in CREBH cleavage and 
activation, investigating why K63-mediated polyubiquitinated CREBH imported more in the 
nucleus is an interesting question. Phosphorylation of CREBH should also be dogged further 
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since TRAF6-mediated ubiquitination is involved in kinase docking and recruitment (107). 
Lastly, usage of CREBH exogenous expression under sepsis or particular bacterial infections 
needs to be tested and validated. This study can potentially lead to a new therapeutic 
approaches, offering benign opportunity to treat the diseases. 
  To summarize, our study revealed a novel crosstalk pathway that involves TLR4 
signaling and CREBH. Low levels of endotoxin induce cleavage and activation of CREBH in 
the liver. Activated CREBH control the expression of the apolipoprotein A IV and the 
inflammatory cytokine IL-6. Targeting the expression of CREBH under disease conditions for 
therapeutic purposes may lead to novel approaches toward alleviating sepsis-related 
complications. 
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Figure 22. Working model for TLR4 mediated cleavage of CREBH and hepatic 
modulation under LPS treatment  
Working model of our hypothesis. LPS upon binding to TLR4 receptor induce activation 
of TL4 receptor signaling pathway. TRAF6 of TLR4 signaling pathway are involved in 
direct cross talk with CREBH for its subsequent activation through K63 ubiquitination. 
PI3K-Akt axis pathway triggered by TLR4 receptors also plays role, but the exact 
mechanism is unexplained. These signaling pathways leads to CREBH translocation and 
cleavage into active form of CREBH. Active CREBH translocates to nucleus inducing 
transcription of IL-6 and Apo A-IV involved in response to LPS stimulation. Apo A-IV 
modulates levels of serum HDL in TLR4-CREBH dependent manner, while TLR4-
CREBH also regulates low levels of IL-6 production from hepatocytes. 
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APPENDIX A 
 
• Mouse Il-6 promoter sequence:  
 
AGCTAGCTAAGATACAATGAGGTCCTTCTTCGATATCTTTATCTTCCATATACCATGAATCAAAGA
AACTTCAACAACATGAGGACTGCAACAGACCTTCAAGCCTCCTTGCATGACCTGGAAATGTTTTGG
GGTGTCCTGGCAGCAGTGGGATCAGCACTAACAGATAAGGGCAACTCTCACAGAGACTAAAGGTC
TTAACTAAGAAGATAGCCAAGAGACCACTGGGGAGAATGCAGAGAATAGGCTTGGACTTGGAAG
CCAAGATTGCTTGACAACAGACAGAAGATATTTCTGTACTTCACCCACTTTACCCACCTGGCAACT
CCTGGAAACAACTGCACAAAATTTGGAGGTGAACAAACCATTAGAAACAACTGGTCCTGACAAGA
CACAGGAAAAACAAGCAATATGCAACATTACTGTCTGTTGTCCAGGTTGGGTGCTGGGGGTGGGA
GAGGGAGTGTGTGTCTTTGTATGATCTGAAAAAACTCAGGTCAGAACATCTGTAGATCCTTACAGA
CATACAAAAGAATCCTAGCCTCTTATTCATGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG
TGTGTGTGTATGTGTGTGTCGTCTGTCATGCGCGCGTGCCTGCGTTTAAATAACATCAGCTTTAGCT
TCTCTTTCTCCTTATAAAACATTGTGAATTTCAGTTTTCTTTCCCATCAAGACATGCTCAAGTGCTG
AGTCACTTTTAAAGAAAAAAAAGAAGAGTGCTCATGCTTCTTAGGGCTAGCCTCAAGGATGACTT
AAGCACACTTTCCCCTTCCTAGTTGTGATTCTTTCGATGCTAAACGACGTCACATTGTGCAATCTTA
ATAAGGTTTCCAATCAGCCCCACCCACTCTGGCCCCACCCCCACCCTCCAACAAAGATTTTTATCA
AATGTGGGATTTTCCCATGAGTCTCAAAATTAGAGAGTTGACTCCTAATAAATATGAGACTGGGGA
TGTCTGTAGCTCATTCTGCTCTGGAGCCCACCAAGAACGATAGTCAATTCCAGAAACCGCTATGAA
GTTCCTCTCTGCAAGTAAGTGAAGGCAGTTCCTTGCCCTCTGGCGGAGCTATTGAGACTGTGAGAG
AGGAGTGTGAGGCAGAGAGCCAGCATTGTGGGTTGGCCAGCAGCCATCAGCTAGCAGCAGGCGCC
CAACTGTGCTATCTGCTCACTTGCCGGTTTTCCCTTTTCTCCACGCAGGAGACTTCCATCCAGTTGC
CTTCTTGGGACTGATGCTGGTGACAACCACGGCCTTCCCTACTTCACAAGTCCGGAGAGGAGACTT
CACAGAGGATACCACTCCCAACAGACCTGTCTATACCACTTCACAAGTCGGAGGCTTAATTACACA
TGTTCTCTGGGAAATCGTGGAAATGAGAAAAGAGGTGGGTAGGCTGTGAAACTGATGAAGACCCA
GTGTGGGCGTCCATTCATTCTCTTTGCTCTTGAATTAGAAATTCTCTGCTGGGATCTAGGGCCCTTA
GGA 
 
 
• Mouse APOA4 promoter sequence: 
GAGCTCGGGGAAGCTCGAGCCCTGTGGGGAGCCATGCAGTGCAGTGGGGCCCAGCAGAGGAGCA
CAGGTATCCAGCTGTCTTCAGTCCCATGAGACAAGCTAATCTGGACACATTTTAAAAAATGGATGG
CAACACAGCAAATCAGACTGGGCACAATCGTGGTCTATTCTAATGGCTGTCATTTCACAAATGCTG
TCTTGTGGATGGCAGTCAATGGGACAGTATGATGGATGCCCTCATCTAGTCCCTGGTGTGGTCCAC
TGAGGCTCCACACTGACCACAGCCTGGCATCTTGCCTGTGGATATCTGCTGCAATTGTATGTGTGG
ACACATGTGGAGTCTCAGTAGGAGACCTCAAAAAACTCACTTTCCACAGCAGTGTCTGTCACCTTC
TGTGGGGGGGGGGGGGGTGGGAAGAGAGAGAGAGGGAGAGAGGGAGAGAGAGAGGGAGAGAG
AGAGAGGAGTCACTCTGCATGGCTCTTGCATATGGCTGAGAACAGTGGGGCAGCAATCAAGCCTT
AGCCAGCCCTGCTCTCTCACTGTTGCCTCTAGCCCACTTGGTGACCCTCTGAGGGAAAGGGTGGCT
CTCCCTCTGCCACTGTCAGGAGAGGATCAGGTTCTCTCCTTCCTTCCTGTGCTGATGCACACAGAA
AATCATTGTCATTAATTTCAGCCCTTACTCTGGGCTAAGCTCCCTGCAGCCATCTCACAAGTACCAC
CTAATTTAATGTAACAAACTACACATTGTTCAAAAGAGAAACTTGAAGCTTCATGATAACTGGACG
GAGGTGAGCCAGCTTGACAGTCATGAGATACAAAGCCCACTATGATTAACTCCTTTGATCCTGGGT
TCTGATCCTCTCCTGACCAAGGGTATCACAGACACCTCAACTGAGGCTCACTGTCTGCTGCAGCCC
TATGCCATCTCTGGGCCTGGTACCATCTCTGTAGCTGATGTTCTGAGACAAAGTTCAGGTTGGTGG
CAGCTGTCAGACTGGTGGCTGTCTCACTGGGGTGGAAAGAGGAGACCTGGACCTTGTTCTCTCAGA
CTGGCACAGACCCAGGGCTGCCAACCGGGCCTCTGGGGCCTCAGTTCTGTTCAGGGACTCCCCTAG
ACTCCCAGGCTCATTCCTCCTGAAGTTTCTGGCTATCCTTCCCAGCCTCTTGGACAGGGTGGAGCCA
ACTCAAGAAGACTGCTTCCCTCTGCTGCCTGTGTGCTGTCAGCTTCCACGTTGTCTTAGGGCCACTA
AAGTCCAAGAGGCCTCCTGGGAGTGTGTCACCTTCCAACGTGGAGTCACACTGGGGAGGAGGCGG
GGAGAGAGGGCTGGAGGGGCTTTAAATGAGTGGCTGGCCTTGCCTGCAGTCAATCTGCACAGGGA
CACAGGTACACCGTTTCTTCTGACTCCGGGAAACATCCAGTGTAGCCGAAACTGTCCCAGCCCAGT
GAGGAGCCCAGGATGTTCCTGAAGGCTGCGGTGCTGACCCTGGCCCTGGTGGCCATCACCGGTGA
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GTAGACACTGCACCTGGGAGGCAGCAAGAAAAGCCAGCTCTAGAACTGGCGGACAGCTCGGGGT
GGCCTTGTATTTGCCCAGCAGCTCATAGGAGAACAGGCCTTTGTTCTCCCTGGCACTTGTGCTCCCT
GGGTTATCCCAGGGATGGGGCAATGGTTTGGGTTATCCAAACTCCAACATTATCCAGCTCAGAGCT
GAGGCAGAGGGGCCAGGAGAGAGATGATCCTCATAAAGTTGCCTTCTGCTCTCTCTCTGCCCAGGC
ACCCGGGCTGAGGTCACTTCGGACCAGGTGGCCAATGTGGTGTGGGATTACTTTACCCAGCTAAGC
AACAATGCCAAGGAGGCTGTAGAACAG 
 
Figure 23 Sequence of mouse il6 and APOA4 gene promoter retrieved using Genomatix 
software. 
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APPENDIX B 
 
ChIP Primer sequence: 
 
 
  
Negative 
control 
primer Forward CATGGATGTATGCTCCCGACT 
  Reverse GGAGCTCAGTCTGTGTCCAG 
Il6  Forward GGAGAGGAGTGTGTGTCTT 
  Reverse GCGCATGACAGACGACACA 
ApoA4 Forward CAGGGTCCAGCCAACTCAAG 
  Reverse CTCCACGTTCGAAGGTGACA 
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Name  Type Sequence  
Fgf21 
Forward GCTGCTGGAGGACGGTTACA 
Reverse CACAGGTCCCCAGGATGTTG 
Apoa4 
Forward AGCTTCCACGTTGTCTTAGGG 
Reverse TGTGACTCCACGTTGGAAGG 
Apob 
Forward CGTCTGGGCTCAAGATGAAGT 
Reverse CTGGACACCGCTGGAACTTT 
Bdh1 
Forward AGATGCGGCTAGTGGCAAAG 
Reverse CAGTTCCTTGACCCCAGCAT 
ApoA5 Forward TCCTCGCAGTGTTCGCAAG 
  Reverse GAAGCTGCCTTTCAGGTTCTC 
Apoc2 Forward CTCTGCTGGGCACGGTGCA  
  Reverse GCCGCCGAGCTTTTGCTGTAC 
ApoA1 Forward AGCTGAACCTGAATCTCCTG 
  Reverse CAGAGAGTCTACGTGTGT 
Pck1 Forward CTCAGCTGCATAACGGTCTG 
  Reverse CTTCAGCTTGCGGATGACAC 
Cpt1a Forward AGAATCTCATTGGCCACCAG 
  Reverse CAG GGTCTCACTCTCCTTGC 
Stat3 Forward  AACGTCAGCGACTCAAACTG 
  Reverse  CCCGTACCTGAAGACCAAGTT 
Saa Forward CGGGACATGGAGCAGAGG 
  Reverse TTGCCACTCCGGCCC 
Sap Forward TGTCTGGGATTGAGATCTTACAACA 
  Reverse CTGCCGCCTTGACCTCTTAC 
Tlr2 Forward CCATTGAGGGTACAGTCGTCG 
  Reverse GGCATTAAGTCTCCGGAATTATC 
Tlr 3 Forward AGCCTTATACCATAAAAG 
  Reverse CAGTTCAGAAAGAACGG 
Tlr 4 Forward GGAAGGACTATGTGATGTGAC 
  Reverse GCTCTTCTAGACCCATGAAATTGG 
Ccl2 Forward CACTCACCTGCTGCTACTCA 
. Reverse GCTTGGTGACAAAAACTACAGC 
Ccl3 Forward CCATATGGAGCTGACACCCC 
  Reverse GTCAGGAAAATGACACCTGGC 
Rplpo Forward AGACAAGGTGGGAGCCAGCGA 
  Reverse GCGGACACCCTCCAGAAAGCG 
Actin Forward  GATCTGGCACCACACCTTCT         
  Reverse GGGGTGTTGAAGGTCTCAAA 
Il6 Forward  CCCAATTTCCAATGCTCTCCT 
  Reverse TGAATTGGATGGTCTTGGTCC 
Tnfα Forward CCA ACG CCC TCC TGG CCA AC 
  Reverse GAG CAC GTA GTC GGG GCA GC 
Quantitative RT-PCR primer sequence: 
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Bacterial endotoxins can induce a variety of physiological changes in the host.  This 
effect is not only restricted to inflammatory changes but also comprises metabolic changes in 
the host body. Lipopolysaccharide (LPS), one of the key components of the bacterial cell walls, 
is capable of triggering host metabolic changes. Hyperlipidemia usually accompanies with high 
endotoxin levels as well as inflammation. Lipid metabolism disorders are one of the common 
hallmarks of a patient with sepsis or high levels of endotoxin through diet. Previously, we have 
identified an endoplasmic reticulum (ER) anchored liver-specific transcription factor CREBH 
(cAMP-responsive element-binding protein, hepatocyte-specific), which is activated by ER 
stress, inflammatory stimuli, and metabolic signals. Proinflammatory cytokines TNFα, IL6, 
and IL1β, bacterial endotoxin lipopolysaccharide, insulin signal, saturated fatty acids, nutrient 
starvation, or atherogenic high-fat (AHF) feeding, can all induce expression and/or activation 
of CREBH in the liver. In this study, we demonstrate that CREBH acts a key player in mounting 
an acute phase response against endotoxemia by modulating apolipoproteins. Endotoxin LPS 
shock in the body induces activation of the TLR4 signaling pathway in mouse liver. Upon 
triggering TLR4 signaling pathway, LPS stimulates cleavage and activation of CREBH 
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transcription factor LPS induces the interaction between CREBH and TNF receptor-associated 
factor 6 (TRAF6), an E3 ubiquitin ligase that plays a key role in mediating TLR signaling. 
While LPS-induced TRAF6-CREBH interaction relies on MyD88, TRAF6 mediates the 
ubiquitination of CREBH to facilitate CREBH activation upon LPS challenge. Functionally, 
CREBH directly activates expression of the gene encoding Apolipoprotein (Apo) A IV and IL6 
under LPS challenge, leading to modulation of high-density lipoprotein (HDL) in animal 
models. In summary, my study suggested that TLR-dependent, LPS-induced CREBH 
activation may represent a host defense response to bacterial endotoxin by modulating 
apolipoproteins. Targeting the expression of CREBH under disease condition may represent a 
novel approach towards alleviating the sepsis-related complications. 
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